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ABSTRACT 
Herein detailed are the syntheses, properties, and applications of metal-oxide nanosubstrates 
covalently functionalized with two classes of materials, inorganic macrocycles called 
corroles, and genomic deoxyribonucleic acid (DNA).  These products have found biomedical 
applications in tumor imaging and chemotherapeutic sequestration, respectively.  Both 
classes of prepared materials are the first of their kind.   
Corroles are tetrapyrrolic macrocycles, which have found applications in tumor imaging and 
treatment, catalysis, solar fuels, and energy conversion.  The direct functionalization of 
metal-oxides with inorganic macrocycles, including corroles, has largely revolved around 
the formation of hydrogen bonding type interactions between the substrate and the ligand.  
Hydrogen bonding motifs result in materials with only moderate stability due to solvent 
dissolution.  In the first three chapters of this thesis, the scalable preparation of 5,10,15-
(trispentafluorophenyl) corrole and its subsequent covalent functionalization of metal-oxide 
surfaces are discussed. 
Chapter 1 details mechanistic elements of the oligomerization and oxidative cyclization of 
5,10,15-(trispentafluorophenyl) corrole from pentafluorobenzaldehyde and pyrrole.  Prior to 
this work the synthesis of triperfluoroaryl corroles was dangerously exothermic and could 
only be carried out on milligram scale.  Mechanistic insights led to a safe and scalable 
synthesis of the desired corrole species, achieving a 17.0 % yield (4.58 g).  A detailed 
discussion of the covalent functionalization of the surface of TiO2 with chlorosulfonated 
derivatives of 5,10,15-tris(pentafluorophenyl) corrole is presented in Chapter 2.  The 
chlorosulfonated species investigated include the freebase, gallium, and aluminum corroles.  
Hydroxyl groups on the metal-oxide react with the chlorosulfonyl groups of the corrole ring 
via nucleophilic attack, resulting in the formation of sulfonic ester linkages.  The aluminum 
species was further investigated as a potential near-infrared optical contrast agent.  The 
details of this study, described in Chapter 3, include imaging experiments with immortalized 
human cancer lines and harvested mouse hepatocytes.  This nanoconjugate exhibited low 
toxicity and efficient cellular uptake. 
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Conventional chemotherapy agents that target DNA are notorious for producing severe 
side-effects.  Sequestering chemotherapeutics that enters systemic circulation, in a process 
deemed “ChemoFiltration,” is a strategy for reducing off-target toxicity.  Materials capable 
of such activity have yet to be fully realized.  Reported in Chapter 4 are the first methods 
covalent attachments of genomic DNA to surfaces, namely magnetite (Fe3O4) nanoparticles, 
via two separate strategies.  These materials show efficacy in removing doxorubicin, 
cisplatin, and epirubicin from biologically relevant solutions.  A device coated with this 
material demonstrated in vivo activity in a porcine model.    
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I n t r o d u c t o r y  R e m a r k s  
I came to Caltech to study inorganic chemistry.  I thought this implied that I would be making 
complexes and analyzing them.  For better or for worse, my initial chemistry did not work 
and I took what I thought would be a brief break to investigate surface functionalization with 
inorganic ligands.  This “brief break” wound up turning into nearly my whole Caltech career.   
My advisors, Harry and Bob, suggested that rather than rewrite my work, I reformat three 
published works into discreet chapters for my thesis.  I tell this story in reverse order as the 
first chapter of the thesis is the most recent corrole paper published.  This chapter describes 
the synthesis of the parent corrole, 5,10,15-tris(pentafluorophenyl) corrole, which will be the 
star of this thesis.  The second and third chapters describe the functionalization of this corrole, 
its covalent coupling to surfaces, and potential applications.  Despite the publication years 
being jumbled, this seems like a fairly logical path to trace. 
The final chapter of my thesis is an unpublished manuscript on surface functionalization of 
metal-oxides with genomic DNA.  This work, while not traditionally inorganic as I had 
expected to do through my career, highlights my interest in surface chemistry of all varieties.  
As this work has not yet been seen by the world, I hope you find it enjoyable! 
 
 
  
2 
C h a p t e r  1  
CONTROL OF OLIGOMERIZATION AND OXIDATION STEPS IN THE 
SYNTHESIS OF TRIS(PENTAFLUOROPHENYL)CORROLE 
Although this work was the last published corrole paper in this dissertation, herein discussed 
is the work that would make corrole use both scaleable and industrially applicable.  At the 
point in which Katie, my undergraduate student, and I approached Scott Virgil about 
synthetic corrole scale-up, we had already covalently functionalized TiO2 surfaces with 
chlorosulfonated metalo- and freebase-derivatives of 5,10,15-tris(pentafluorophenyl)corrole.   
The initial corrole syntheses were dangerous and low yielding.  The traditional workhorse 
reaction was run solvent free; upon introduction of dilute catalyst to the reaction mixture, the 
contents of the reaction would start to boil vigorously.  This uncontrollable exothermic 
reaction would then spew a black almost tar-like material all over the fumehood.  Whatever 
material remained was sonicated with large quantities of solvent to promote dissolution, at 
which point it was chemically oxidized.  To improve safety and somewhat temper the 
exotherm, no large scale reactions were run.  Instead, fifteen to twenty microscale reactions 
were run at which point the tar like material was collected in bulk for oxidation.   
Nonetheless, with materials in hand we carried out the chlorosulfonation and subsequent 
metalation procedures of the parent corrole.  These steps were quite low yielding (and are 
discussed in subsequent chapters) but we were able to access the surface functionalized 
materials.  In vitro optical imaging of these materials were studied in collaboration with 
researchers at Children’s Hospital Los Angeles.  We observed that these materials were in 
fact strong candidates as tissue imaging agents.   
We hoped to prepare more materials on scale so I approached Scott Virgil in the Caltech 
Catalysis Center.  We believed that by using robotic methods, we could scale up the 
microreactions and keep our hands away from the violent exotherm.  Thankfully, Scott had 
a different idea!  We would develop methods for scaling the reaction, whilst controlling the 
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exotherm.  At the same time, we would also improve the yield of the reaction itself.  During 
the process of developing this reaction, we nearly doubled the yield of the traditional 
pentafluorophenyl corrole synthesis but at the same time could work on scales more than an 
order of magnitude larger! 
In addition to all of this synthetic work, Katie, my undergrad, while washing out fritted 
funnels contaminated with tris(pentafluorophenyl) corrole, unintentionally (and very luckily) 
started the growth of x-ray grade crystals that were essential for the assignment of the 
positions of the pyrrole protons in the core of the corrole ring.   
Described below are our efforts to understand the fundamental steps in the corrole forming 
reaction.  We no longer considered the corrole synthesis to be a single two-step reaction; 
instead, we observed that each stage of the reaction could be carefully controlled and 
optimized.  In the process of this work, we produced over fifty grams of pure corrole.  This 
is a supply for several graduate lifetimes!     
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CONTROL OF OLIGOMERIZATION AND OXIDATION STEPS IN 
THE SYNTHESIS OF TRIS(PENTAFLUOROPHENYL)CORROLE 
Reproduced with permission from: Carl M. Blumenfeld, Katherine J. Fisher, Lawrence M. 
Henling, Robert H. Grubbs, Harry B. Gray, and Scott C. Virgil. European Journal of Organic 
Chemistry, 2015, 3022-3025.  Copyright 2015 Wiley-VCH Verlag GmbH & Co.  
Introduction 
The field of corrole synthesis, including its applications, has burgeoned over the last 
fifteen years.  As late as 1998, corroles and their metal complexes found no application.[1] 
Owing to fundamental work on the original syntheses of corroles from Gross and co-workers, 
the field has grown enormously.[1, 2]   Corroles have found applications in molecular tumor 
imaging and treatment,[3] solar fuels chemistry,[4] chemical catalysis,[5] and nanomaterial 
development.[6] 
The first synthesis of a corrole dates to 1965 in which Kay and Johnson prepared 
corrole and corrolato species from a deoxybiladiene intermediate (7).  It was not until 1993, 
however, that a meso-aryl-substituted corrole was prepared that led to applications in 
catalysis (8).  In seminal work in the late 1990s, Gross and co-workers discovered a synthesis 
of tris(pentafluorophenyl)corrole (1) from readily available starting materials, 
pentafluorobenzaldehyde (2) and pyrrole (3) (1, 2).  This discovery changed the course of 
corrole chemistry, as now investigation could explore both the fundamental properties as 
well as practical applications of these macrocyclic compounds. 
Fully 15 years after the Technion work, we still do not have a clear understanding of 
the individual steps leading to the corrole formation.  Indeed, the situation is much like the 
state of porphyrin synthesis before the impressive contributions by Lindsey (9).  We set as a 
goal the elucidation of each step in the corrole-forming sequence (Scheme 1). 
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Results and Discussion 
Our initial experiments were aimed at isolating the pyrrole-aldehyde oligomerization 
reaction from the subsequence oxidation steps of corrole synthesis.  A series of screens was 
conducted to assess the influence of reaction concentration, temperature, pyrrole to aldehyde 
ratio, and acid catalyst concentration.  The reactions were analyzed by LC-TOF and revealed 
several correlations according to the mechanism shown (Scheme 2). 
Scheme 1. Synthesis of corrole (TFA = trifluoroacetic acid). 
Scheme 2. Mechanism of condensation of 2 and 3. 
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 It became quickly apparent that a clean condensation could be optimized to achieve 
the predominant production of linear, fully alternating pyrrole-capped oligomers.  We sought 
to optimize the conditions for the formation of oligomers 4-10, expecting that compound 6 
would prove to be a favorable precursor to 1 by oxidation (Scheme 3). 
The best conditions for generating a predominance of the fully capped species 
included increased reaction concentration and increased number of pyrrole equivalents.  
However, under concentrated reagent conditions or as a neat mixture, the reaction is strongly 
exothermic and the exotherm is uncontrollable on a scale above 5 mmol.  We therefore 
performed a series of automated screens to optimize the parameters of temperature, dilution, 
pyrrole equivalents, and trifluoroacetic acid (TFA) catalyst loading.  Elevated reaction 
temperatures were found to lead to a flattening of the oligomer distribution favoring 7-10 
and still larger oligomers while decreasing the contribution of 6 to the final product mixture.  
Dilution with dichloromethane was evaluated to moderate the reaction and control the 
exotherm.  The initial observations from these dilution experiments revealed the presence of 
Ar-terminal intermediates in the product mixture (Scheme 2) and a prevalence of higher-
massed products (10).  The presence of Ar-terminal intermediates in the product mixture was 
especially undesirable, even in small amounts, due to their eventual conversion upon 
subsequence oxidation to the porphyrin that we found difficult to separate from 1.  Therefore, 
additional equivalents of pyrrole were screened to achieve the complete pyrrole-capping of 
oligomers and this had the added benefit of sharply curtailing the product distribution past 
Scheme 3. Selective preparation of oligomers 4-10. 
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the desired product 6.  Under the optimized conditions for the scale-up procedure (20 g of 
2), the yield of compound 6 was maximized (Figure 1) with a favorable exponential decline 
of higher oligomers (11, 12).  In order to unambiguously characterize the products of this 
reaction and to confirm the predominance of 6 in the product mixture, a smaller scale reaction 
mixture (1.5 g of 2) was purified by preparative HPLC affording the individual yields shown 
in Scheme 3. 
Full characterization of the individual products form this reaction required an 
appreciation of the stereoisomerism inherent to oligomeric species with sequential 
stereogenic centers (13).  Although standard reversed phase HPLC analysis of products 4-10 
gave no separation of the stereoisomers present, chiral supercritical fluid (SFC) experiments 
(Figure 2, left) readily separated individual isomeric species present in the products 4-7.  In 
addition, high-field 1H NMR spectra (Figure 2, right) revealed individual methane 
resonances for multiple stereoisomers in these fractions.  Although 4 showed a single peak  
under each measurement, the product 5 gave a 1:1 ratio of dl and meso isomers in the 1H 
NMR spectrum and a 1:2:1 ratio in the chiral SFC analysis consistent with a statistical ratio 
of these isomers produced under the reaction conditions.  In contrast, a non-statistical 
distribution of isomers was apparent from the analysis of 6 (0.27:0.32:0.29:0.12 ratio in SFC 
and 0.31:0.57:0.12 ratio by 1H NMR) (14).  Finally, the spectra of 7 appeared to show the 
Figure 1. HPLC analysis (Agilent 2.1 x 50 mm Eclipse Plus C8, 60-
100% ACN/H2O, 254 nm) of the product mixture from teh reaction 
of 2.8 equiv. of 3 with aldehyde 2 in CH2Cl2 (2.0 M) with 1.9 mol-% 
TFA at 15-40 ˚C. 
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expected six isomeric species in the 1H NMR spectrum while giving a complex series of 
peaks in the SFC analysis.  Importantly, the isolation and unambiguous characterization of 
these linear fully alternating pyrrole-capped oligomers including 6, demonstrates that for this 
perfluorophenyl series the entire acid-catalyzed sequence of reactions operates as a simple 
condensation without any pyrrole-pyrrole coupling events or cyclization to corrole 
precursors (15, 16). 
The controlled DDQ (2,3-dihcloro-5,6-dicyano-1,4-benzoquinone) oxidation of the 
crude reaction mixture presents an additional challenge in the corrole-forming process.  In 
preparative runs, the generation of electrophilic species from the crude mixture of 4-10 can 
lead to competing polymerization reactions, thus decreasing the isolate yield of 1.  We 
screened conditions for optimization using samples of pure 6 prepared above and then 
evaluated the factors necessary to achieve a high yield of 1 on the preparative scale from the 
mixture of 4-10.  Gratifyingly, the pure isomer 6 was effectively converted to corrole 1 in 
Figure 2. SFC chromatographic analysis (two Chiralcel® 4.6  260 
mm AD-H columns, 7% 2-propanol in CO2 at 40 ˚C, 3 mL/min) and 
1H NMR (600 MHz, C6D6) analysis of the purified products 4-7 
(spectra a-d). 
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84% isolated yield when treated with a THF solution of 3.3 equiv. of DDQ in 
dichloromethane at 15 ˚C.  Corrole 1 was readily observed during the initial phase of the 
DDQ addition suggesting that the three 2e- oxidations proceed as a cascade to the stable 
corrole rather than an accumulation of sequentially oxidized species.  Based on this 
observation, it is reasonable to believe that the key intramolecular cyclization event occurs 
immediately after reaction with the first equivalent of DDQ followed by two facile oxidations 
to 1 as shown below (17). 
When approaching the oxidation of the unpurified mixture of 4-10, experimental 
conditions were evaluated in order to minimize the intermolecular electrophilic reactions that 
could compete with the cyclization shown in Scheme 4.  The conditions described for the 
aforementioned oligomerization (Scheme 3) were chosen to minimize the contribution of 
oligomer 4 which generated an undesirable contribution of electrophilic species.  In addition, 
removal of excess pyrrole in vacuo prior to the DDQ oxidation step dramatically reduced the 
formation of polymeric byproducts and simplified the chromatographic purification of 1.  
Under the optimized scale-up procedure (beginning with 20 g of 2, Scheme 2 and Scheme 
4), the addition of a THF solution containing 1.0 equiv. of DDQ to the dichloromethane 
solution of 4-10 at 5 ˚C afforded 1 in 17.0% yield after chromatographic purification and 
recrystallization. 
 
Scheme 4. DDQ oxidation of 6 leading to corrole 1. 
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Although the crystal structure of 1 has been previously reported, we found that 
crystals of the formula 1•(ace)2 were obtained readily from acetone by slow evaporation. 
The X-ray structure shown in Figure 3 was freely refined to reveal the hydrogen atom 
coordinates within the corrole ring system (18). 
Conclusions 
We have revisited the mechanism of corrole oligomerization and cyclization steps in 
an effort to achieve a scalable synthesis with an increased yield (19).  Isolated precursor 6, 
upon selective oxidation, afforded a favorable yield of 84% while a scalable synthesis 
directly from 2 and 3 without intermediate purification afforded 17.0% of the corrole 1 over 
two steps.  This speaks to the intricacy of the oxidation of the bulk reaction mixture and the 
requirement for the optimization of both steps individually.  We hope that these advances in 
mechanistic understanding will facilitate the further development of the corrole field due to 
more facile access to corrole ligands. 
Figure 3. X-ray structure of 1 obtianed from crystals of the formula 
1•(ace)2. 
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Experimental Section 
A mixture of 2 (20 g, 0.102 mol), dihchloromethane (15 mL) and 3 (20 mL, 19.3 g 
0.29 mol) in a 500 mL round-bottomed flask was placed in an ice-water bath.  When the 
internal temperature reached 15 ˚C, 1.0 mL of a 5% v/v trifluoroacetic acid solution (0.075 g 
of TFA, 0.65 mmol) in dichloromethane was added with rapid stirring.  After the initial 
exotherm subsided, an additional 2.0 mL of the 5% TFA solution was added.  After 30 min, 
the mixture was filtered through anhydrous magnesium sulfate and concentrated at 0.5 Torr 
and 40 ˚ C.  The viscous liquid was redissolved in dichloromethane (50 mL) and concentrated 
again at 0.5 Torr and 40 ˚C.  A solution of DDQ (22.7 g, 0.10 mol) in tetrahydrofuran (200 
mL) was added to the resulting mixture of 4-10 (Figure 1) in dichloromethane (4000 mL) at 
5 ˚C over 40 min.  After stirring for 6h at room temperature, the mixture was evaporated to 
a volume of 400 mL, diluted with hexane (400 mL) and filtered.  The crude product was 
purified by flash chromatography over silica (1320 g) with 25% dichloromethane/hexanes 
and recrystallized from dichloromethane/hexanes to afford 4.58 g of 1 (17.0% yield) in two 
crops.   
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Supplementary Experimental and Characterization 
Representative Screening Results from the Optimization of Oligomerization and 
Oxidation Steps: Screening experiments of pyrrole:aldehyde ratio, TFA catalyst 
concentration, solvent, and temperature were prepared using the Freeslate Core Module 2 
on a scale of 1 mmol and the crude reaction mixtures were analyzed by LCMS at multiple 
timepoints.  Using the measured relative molar response factors at 254 nM of 1.0, 2.2, 3.5, 
5.1, 6.7, 8.4 for the purified compounds 4-9, respectively, the UV integrations for each 
oligomer were converted to the per cent of theoretical yield of each oligomer.  A 
representative optimization for pyrrole:aldehyde molar ratio is shown in Figure 1 below. 
Optimization experiments for the DDQ oxidation step were conducted in a similar fashion 
using 4,4’-di-tert-butylbiphenyl as an internal standard.   In practice, the optimum number 
of equivalents of DDQ and the yield of 1 were dependent on the composition of 4-10 
present in the oligomer sample subject to oxidation with the best results obtained when 
oligomer 4 was present in lesser amounts.  A representative optimization for the molar ratio 
of DDQ:starting aldehyde on the mixture of 4-10 is shown in Figure 2 below. 
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Procedure for the preparation and preparative HPLC separation of compounds 4-10: 
To a 20 mL scintillation vial with stirbar was added a solution of 
pentafluorobenzaldehyde (1.50 g, 7.65 mmol, 1.0 equiv.) in dichloromethane (2.25 mL) 
followed by pyrrole (2.25 mL, 2.18 g, 32.4 mmol, 4.2 equiv.). The mixture was cooled 
to 15 °C and a solution of 1:19 v/v trifluoroacetic acid in dichloromethane (75 µL, .05 
mmol, 0.006 equiv.) was added.  After stirring for 10 minutes at 15 – 20 °C, an additional 
75 µL of the trifluoroacetic acid solution was added and the mixture was allowed to stir 
at room temperature for 20 minutes. 
Supplementary Figure 2: HPLC % Yield of 4-10 vs. Pyrrole Equivalents. 
4 5 
6 
7 
8 
10 9 
Supplementary Figure 1: HPLC  %  Yield  of  1  vs.  DDQ equivalents 
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The reaction mixture was directly purified by reversed phase preparative HPLC (in 12 
injections of 500 µL each) on a 30 x 250 mm XDB-C18 column (5 µM particle size) 
using an Agilent 1200 preparative HPLC with a flow rate of 50 mL/min (85-100% 
acetonitrile/water) and UV detection at 254 nM. The fractions containing compounds 4-
10 were separately collected in ice-cooled receivers and rotary evaporated to dryness. Care 
was taken to minimize exposure to air and light during the handling and storage of 4-10. 
After dissolving in ether, the products were transferred to individual vials and evaporated 
to afford the pure compounds 4-10 which were pumped under high vacuum for 4 hours. 
2,2'-((perfluorophenyl)methylene)bis(1H-pyrrole) 
C4H4N-CH(C6F5)-C4H4N (4) was obtained as an off-white solid (478 mg, 20.0% yield). 1H 
NMR (600 MHz, CD2Cl2): d 8.20 (br s, 2H), 6.73 (dt, 2H, J = 1.5, 2.7 Hz), 6.14 (q, 2H, J = 
3.0 Hz), 6.01 (t, 2H, J = 3.2 Hz), 5.91 (s, 1H). HR(ESI)-MS (M-H) (M = C15H9F5N2): Calcd 
311.0602, obsd 311.0587. 
2,5-bis((perfluorophenyl)(1H-pyrrol-2-yl)methyl)-1H-pyrrole 
C4H4N-[CH(C6F5)-C4H3N]-CH(C6F5)-C4H4N (5) was obtained as an orange viscous 
liquid (393 mg, 18.4% yield). 1H NMR (600 MHz, CD2Cl2): d 8.20 (br s, 2H), 8.07 and 
8.04 (pair of s, 1H, dl and meso), 6.72 (q, 2H, J = 2.3 Hz), 6.11 (m, 2H), 5.96 (s, 2H), 
5.92 (t, 2H, J = 2.4 Hz), 5.84 (s, 2H). HR(ESI)-MS (M-H) (M = C26H13F10N3): Calcd 
556.0866, obsd 556.0851. 
5,5'-((perfluorophenyl)methylene)bis(2-((perfluorophenyl)(1H-pyrrol-2-yl)methyl)-1H-
pyrrole) 
C4H4N-[CH(C6F5)-C4H3N]2-CH(C6F5)-C4H4N (6) was obtained as a yellow powder (459 
mg, 22.4% yield). 1H NMR (600 MHz, CD2Cl2): d 8.20 (br s, 2H), 8.00 – 8.10 (m, 2H), 6.73 
(m, 2H), 6.12 (m, 2H), 5.96 (m, 2H), 5.86-5.91 (m, 4H), 5.84 (s, 2H), 5.78 and 5.77 (pair 
of s, 1H). HR(ESI)-MS (M-H) (M = C37H17F15N4): Calcd 801.1130, obsd 801.1110. 
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2,5-bis((perfluorophenyl)(5-((perfluorophenyl)(1H-pyrrol-2-yl)methyl)-1H-pyrrol-2-
yl)methyl)-1H- pyrrole 
C4H4N-[CH(C6F5)-C4H3N]3-CH(C6F5)-C4H4N (7) was obtained as an orange viscous 
liquid (318 mg, 15.9% yield). 1H NMR (600 MHz, CD2Cl2): d  8.20 (br s, 2H), 8.00 (m, 
3H), 6.71 (m, 2H), 6.10 (m, 2H), 5.96 (m, 2H), 5.90 (m, 2H), 5.87 (m, 4H), 5.83 (s, 2H), 
5.76 (pair of s, 2H). HR(ESI)-MS (M-H) (M = C48H21F20N5): Calcd 1046.1394, obsd 
1046.1395. 
5,5'-((perfluorophenyl)methylene)bis(2-((perfluorophenyl)(5-
((perfluorophenyl)(1H-pyrrol-2- yl)methyl)-1H-pyrrol-2-yl)methyl)-1H-pyrrole) 
C4H4N-[CH(C6F5)-C4H3N]4-CH(C6F5)-C4H4N (8) was obtained as an orange viscous 
liquid (162 mg, 8.2% yield). 1H NMR (600 MHz, CD2Cl2): d  8.18 (br s, 2H), 8.03 (m, 
4H), 6.71 (m, 2H), 6.10 (m, 2H), 5.95 (m, 2H), 5.89 (m, 2H), 5.87 (m, 6H), 5.83 (s, 
2H), 5.76 (m, 3H). HR(ESI)-MS (M-H) (M = C59H25F25N6): Calcd 1291.1658, obsd 
1291.1627. 
2,5-bis((perfluorophenyl)(5-((perfluorophenyl)(5-((perfluorophenyl)(1H-pyrrol-2-yl)methyl)-
1H-pyrrol- 2-yl)methyl)-1H-pyrrol-2-yl)methyl)-1H-pyrrole 
C4H4N-[CH(C6F5)-C4H3N]5-CH(C6F5)-C4H4N (9) was obtained as a light brown viscous 
liquid (85 mg, 4.3% yield). 1H NMR (600 MHz, CD2Cl2): d  8.18 (br s, 2H), 8.02 (m, 
5H), 6.70 (m, 2H), 6.09 (m, 2H), 5.95 (m, 2H), 5.89 (m, 2H), 5.87 (m, 8H), 5.83 (s, 
2H), 5.76 (br s, 4H). HR(ESI)-MS (M-H) (M = C70H29F30N7): Calcd 1536.1922, obsd 
1536.1883. 
5,5'-((perfluorophenyl)methylene)bis(2-((perfluorophenyl)(5-((perfluorophenyl)(5- 
((perfluorophenyl)(1H-pyrrol-2-yl)methyl)-1H-pyrrol-2-yl)methyl)-1H-pyrrol-2-
yl)methyl)-1H-pyrrole  
C4H4N-[CH(C6F5)-C4H3N]6-CH(C6F5)-C4H4N (10) was obtained as a light brown viscous 
liquid (32 mg, 1.8% yield). 1H NMR (600 MHz, CD2Cl2): d  8.18 (br s, 2H), 8.02 (m, 
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6H), 6.70 (m, 2H), 6.09 (m, 2H), 5.94 (m, 2H), 5.90 (m, 2H), 5.87 (m, 10H), 5.82 (s, 2H), 
5.75 (br s, 5H). HR(ESI)-MS (M-H) (M = C81H33F35N8): Calcd 1781.2186, obsd 1781.2135. 
Procedure for the DDQ oxidation of purified oligomer 6: 
In a 40 mL scintillation vial with stirbar, a solution of oligomer 6 (364 mg, 0.45 
mmol) in 25 mL dichloromethane was treated by the dropwise addition over 10 minutes 
of a solution of 2,3-dichloro-5,6- dicyano-1,4-benzoquinone (341.5 mg, 1.50 mmol, 3.3 
equiv.) in 1.5 mL tetrahydrofuran at 15 °C. The reaction was allowed to proceed with 
stirring at 15 °C for 20 minutes.   After filtration of the cold reaction  mixture  through  
Celite®,  the  filtrated  was  concentrated  to  dryness.  The residue was immediately taken 
up in 1:3 dichloromethane-hexane and purified by column chromatography on silica using 
1:3 dichloromethane-hexanes as eluent. The corrole 1 was obtained as a dark purple powder 
(305 mg, 84% yield). 
Preparation of Tris(pentafluorophenyl)corrole (1): 
To an open 500 mL round-bottomed flask equipped with a stir bar was added 
pentafluorobenzaldehyde (20.0 g, 0.102 mole), dichloromethane (15 mL) followed by 
freshly distilled pyrrole (20 mL, 19.3 g, 
0.29 mole, 2.8 equiv.). The mixture was placed in an ice-water mixture with stirring 
and when the internal temperature reached 15 °C, 1.0 mL of a 5% by volume 
trifluoroacetic acid solution (0.075 g of TFA, 0.65 mmol) in dichloromethane was added 
in one portion with rapid stirring. After 3 minutes, the solution temperature had risen to 40 
°C while stirring in the ice-water bath was continued. (It was found that allowing the 
temperature to rise in this manner ensured that the reaction mixture remained homogeneous 
and this procedure produced the most favorable distribution of the oligomers 4-10.) Once 
the temperature subsided to 30 °C, an additional 2.0 mL of trifluoroacetic acid solution 
(0.15 g of TFA, 1.3 mmol) was added and the reaction was removed from the bath and 
allowed to proceed at room temperature for 30 minutes. The reaction mixture was filtered 
through anhydrous magnesium sulfate and concentrated to a viscous liquid by rotary 
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evaporation using a vacuum pump at 0.5 torr and 50 °C. Complete removal of excess 
pyrrole was achieved by dissolving in 50 mL dichloromethane and rotary evaporation a 
second time. Analysis of the oligomeric mixture by LC-TOF confirmed the presence of 
oligomers 4-10 in relative contributions shown in Figure 1. Integration of the UV signal 
(254 nm) of the HPLC chromatogram revealed that the desired peak corresponding to 
oligomer 6 represented 25.7% of the total integration for the oligomers 4-10. (Using the 
measured relative molar response factors at 254 nM of 1.0, 2.2, 3.5, 5.1, 6.7, 8.4 for the 
purified compounds 4-9, respectively, we estimated that the mole fraction of the desired 
oligomer 6 in this mixture was approximately 26% in reasonable agreement with the 
isolated yield of 6 obtained in the preparative HPLC procedure above.) The mixture 
of oligomers 4-10 was subject to discoloration by air oxidation and was therefore used 
without delay. 
The crude mixture of 4-10 was dissolved in dichloromethane (4000 mL), transferred 
to a 5L round bottomed flask with stirbar and cooled to 5 °C using an ice-water mixture. 
A solution of 2,3-dichloro- 5,6-dicyano-1,4-benzoquinone (22.7 g, 0.100 mole, 1.00 
equiv. based on starting aldehyde) in tetrahydrofuran (200 mL) was added dropwise with 
stirring over 40 minutes while the reaction mixture was maintained at 5 °C. After 
completion of the addition (the complete consumption of 6 and the generation of 1 in 
the reaction mixture could be monitored by LCMS), the reaction mixture was stirred at 
room temperature for 6 hours. The resulting product mixture was then concentrated to a 
volume of 400 mL, diluted with 400 mL hexane and filtered to remove the hydroquinone 
byproduct. After rotary evaporation, the material was dissolved in dichloromethane (100 
mL) with heating until dissolved and flash silica gel (120 g) was added followed by hexane 
(300 mL). The warm mixture was loaded without delay onto a column of 1200g flash (40-
60 uM) silica gel prepared with 1:3 dichloromethane-hexanes. Upon elution of the column 
with 1:3 dichloromethane-hexane as eluant, the strongly colored corrole containing 
fraction was concentrated.   [It was desirable to efficiently separate the less polar orange 
contaminant (described and characterized by Gross3) during this chromatography 
procedure in order to ensure the successful purification of 1 by recrystallization.] The 
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crude corrole 1 was dissolved in dichloromethane (120 mL) with heating and hexane 
was added (180 mL). The mixture was heated to evaporate about half of the 
dichloromethane from the mixture inducing the crystallization of a significant portion of 
the product. After cooling the mixture to 0 °C, the first crop of 1 was collected by filtration 
and washing with cold hexane (3.75 g, 13.9% yield). The filtrate was combined with 
mixed fractions from the first column chromatography and repurified by column 
chromatography to afford, after recrystallization, an additional crop of 1 (0.83 g, 3.1% 
yield). The combined yield of tris(pentafluorophenyl)corrole (1) was 4.58 g, (17.0% 
yield). 1H NMR (600 MHz, CD2Cl2): d 9.17 (d, 2H, J = 3.5 Hz), 8.83 (d, 2H, J = 3.5 
Hz), 8.61-8.66 (m, 4H). HR(ESI)-MS (M+H) (M = C37H11F15N4): Calcd 797.0817, obsd 
797.0825. 
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1H NMR of 4 in CD2Cl2 
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1H NMR of 4 in C6D6 
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1H NMR of 5 in CD2Cl2 
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1H NMR of 5 in C6D6 
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1H NMR of 6 in CD2Cl2 
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1H NMR of 6 in C6D6 
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1H NMR of 7 in CD2Cl2 
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1H NMR of 7 in C6D6 
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1H NMR of 8 in CD2Cl2 
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1H NMR of 9 in CD2Cl2 
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1H NMR of 10 in CD2Cl2 
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X-Ray Structure Determination 
Diffraction data (w-and f-scans) were collected on a Bruker AXS KAPPA APEX II 
diffractometer using an APEX II CCD detector with Triumph graphite monochromated Mo 
Ka fine-focus sealed tube radiation (l = 0.71073 Å) equipped with  an Oxford 700 
Cryostream low-temperature cooler set to 100 K. The structure was solved by direct methods 
using SHELXTi and refined against F2 on all data by full-matrix least squares with SHELXL1 
using OLEX22.   
Compound A14375 crystallizes in the monoclinic space group P21/c (#14) as large 
(several mm in length) purplish-red crystals with a metallic luster. The asymmetric unit 
consists of one corrole and two acetone solvent molecules. Except for the minor orientation 
of one disordered perfluorophenyl group, all non-hydrogen atoms were refined 
anisotropically. The central pentafluorophenyl group is disordered 92:08 by an ~4° tilt 
parallel to the plane of the phenyl ring. The minor component was refined isotropically and 
restrained to have the same geometry as the major component. One of the two acetones is 
disordered 80:20 over two positions. There may be some small disorder in the other as well. 
All hydrogen atoms on the corrole were located in difference maps and freely refined. The 
methyl groups on the solvent acetone molecules were refined as rotating groups with Uiso 
values 1.5 times the Ueq of the bonded atom. There is a hydrogen bond from a pyrrole 
nitrogen to one acetone oxygen. The out of pyrrole plane distances for the hydrogens H1, 
H2, and H4 are 0.37, 0.09, and 0.10Å respectively. The angles between the pyrrole planes 
(N1-N2, N2-N3, N3-N4, N4-N1 respectively) are 157.0, 167.2, 6.6, and 25.5°.  The overall 
conformation of the corrole is similar to that in a structure of an m-xylene solvate reported 
by Gross3 in which the hydrogen parameters were not refined. 
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C h a p t e r  2  
DECORATING METAL OXIDE SURFACES WITH FLUORESCENT 
CHLOROSULFONATED CORROLES 
The work presented in this chapter was the first corrole work I published.  When I first arrived 
at Caltech, I sought to scale the synthesis of a carboxylated corrole for tumor diagnostic 
purposes.  Naturally, this project went horribly and the reproduction of literature seemed 
impossible.  Luckily, I was introduced to Karn Sorasaenee, a wonderful researcher at 
Children’s Hospital Los Angeles, and former Gray group postdoctoral fellow.  He suggested 
that instead we investigate nanoparticle imaging systems based on corrole chemistry.   
We were inspired by some work in Jeremy Weaver’s (a former Gray group member) thesis, 
in which he utilized sulfonic acid functionalized corroles for dye sensitized solar cells.  These 
materials were efficient, however, the dye molecules tended to leach from the surface into 
the electrolyte solution.  To access covalently coupled materials we carried out a dreaded 
chlorosulfonation reaction but left the chlorosulfonyl group intact.  The notion behind 
coupling the dyes to the surface was inspired by the use of chlorosulfonation in organic 
chemistry.  The sulfonyl chloride synthetic handle reacts readily with nucleophiles including 
hydroxyl groups.  We went on to react the hydroxyl-bearing surface of titanium dioxide with 
the chlorosulfonyl group on the corrole ring, to produce a stable, covalent bond in the form 
of a sulfonic ester. 
Having achieved success with the freebase molecule, we investigated two routes to 
metallated species.  We concluded that it was necessary to carefully install metals following 
chlorosulfonation.  The metallated complexes tended to decompose under chlorosulfonation 
conditions.  This was somewhat expected as the chlorosulfonation required the use of neat 
chlorosulfonic acid.   
In preparing these materials we imaged them using confocal fluorescence microscopy.  The 
aluminum corrole nanoconjugate was by far the brightest material.  This helped us elect the 
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imaging candidate described in the following chapter. This work really began my interest 
in surface functionalization…it’s been a good run so far!   
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DECORATING METAL OXIDE SURFACES WITH FLUORESCENT 
CHLOROSULFONATED CORROLES 
Reproduced with permission from: Carl M. Blumenfeld, Robert H. Grubbs, Rex A. Moats, 
Harry B. Gray, and Karn Sorasaenee. Inorganic Chemistry, 2013, 4774-4776.  Copyright 
2013 American Chemical Society 
 
Abstract: 
We have prepared 2,17-bis(chlorosulfonyl)-5,10,15-tris(pentafluorophenyl)corrole 
(1), 2,17-bis(chlorosulfonyl)-5,10,15-tris(pentafluorophenyl)-corrolatoaluminum(III) (1-
Al), and 2,17-bis(chlorosulfonyl)-5,10,15-tris(pentafluorophenyl)-corrolatogallium(III) (1-
Ga).  The metal complexes 1-Al and 1-Ga were isolated and characterized by electronic 
absorption and NMR spectroscopies, as well as by mass spectrometry.  Relative emission 
quantum yields for 1, 1-Al, and 1-Ga, determined in toluene, are 0.094, 0.127, and 0.099, 
respectively.  Reactions between 1, 1-Al, and 1-Ga and TiO2 nanoparticles (NPs) result in 
corrole—TiO2 NP conjugates.  The functionalized NP surfaces were investigated by solid-
state Fourier transform infrared and X-ray photoelectron spectroscopies and by confocal 
fluorescence imaging.  The fluorescence images for 1-Al—TiO2 and 1-Ga—TiO2 suggest a 
promising application of these NP conjugates as contrast agents for noninvasive optical 
imaging.  
In recent years, molecular imaging has attracted much attention in the medical field 
for both the diagnosis of and intervention against disease.1  Although a myriad of imaging 
modalities have enormously contributed to biomedical research,2 probe development is still 
a very high priority.3  Historically, small-molecule and biomolecule contrast agents have 
been prepared and studied in the context of their corresponding imaging modalities.4  More 
recently, nanomaterial probes, such as quantum dots and iron oxide nanoparticles (NPs), 
have been developed and employed in molecular imaging.5  Studies of and interests in these 
nanomaterials as contrast agents also suggest the possibility of extensive probe development 
in biomedical imaging.  In this study, we focus on the use of versatile fluorescent small 
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molecules, namely, corroles, as potential contrast agents in optical imaging.  Corroles are 
facilely modified using multiple approaches including both aromatic and asymmetric 
substitution at the meso-aryl position as well as modification at the β-pyrrolic positions, 
making these tetrapyrrolic macrocycles strong candidates for readily tunable imaging 
systems.6 
Recently, there has been much effort in developing these macrocycles as optical dyes 
because of their unique fluorescence properties.7  Previous imaging studies employing 
corroles have only been pursued with noncovalent assemblies between the macrocycle and 
proteins.8  For the first time, we report the use of corroles as synthons for optical imaging 
agents with applications involving covalently bound NPs.  The preparation of the parent free-
base macrocycle 2,17-bis(chlorosulfonyl)-5,10,15-tris(pentafluorophenyl)corrole (1) has 
been reported;9 however, before our work, the metalated species had not been prepared.  Here 
we report the preparation and characterization of 1, 2,17-bis(chlorosulfonyl)-5,10,15-
tris(pentafluorophenyl)-corrolatoaluminum(III) (1-Al), and 2,17-bis(chlorosulfonyl)-
5,10,15-tris(pentafluorophenyl)corrolatogallium(III) (1-Ga).  In addition, spectroscopic and 
photophysical studies, which serve as a fundamental platform for further development of 
these bis-chlorosulfonated corroles as building blocks for optical contrast agents, will be 
addressed.  We will also discuss surface modification reactions by which 1, 1-Al, and 1-Ga 
can be covalently coupled to TiO2 NP surfaces as well as surface characterization of the 
TiO2—corrole nanoconjugates. 
Corrole 1 has been prepared according to the literature.9  Metal-insertion reactions of 
1 with AlMe3 in a toluene/pyridine mixture at 0 ˚C and GaCl3 in pyridine at reflux afford the 
products 1-Al (26% yield) and 1-Ga (39% yield), respectively (Scheme 1).  Both 1-Al and 
1-Ga were isolated by solvent extraction and obtained as green solids after evaporation to 
dryness.  The metalated products were further purified by acetone/methylene chloride 
assisted filtration followed by the removal of solvents in vacuo. 
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Electronic absorption spectra for 1, 1-Al, and 1-Ga obtained in degassed toluene 
solutions reveal the signature Soret and Q bands for these tetrapyrrolic macrocycles (Figure 
1).  The electronic absorption data for the chlorosulfonated corroles are also given in Table 
1.  Compared to the parent compound 1, each of the metalated chlorosulfonated corroles 1-
Al and 1-Ga exhibits a sharper Soret band with a vibronic shoulder to the left (characteristic 
of the metalated species) that is blue-shifted at 424 and 426 nm, respectively, as shown in 
Figure 1.  The Q bands for both 1-Al and 1-Ga are also narrower and are observed at 592 
and 588 nm, respectively.  This could be further explained by the presence of a single 
absorbing species for the metalated corroles, while the nonmetalated corrole could exhibit 
two tautomeric forms.10g,h 
 
 
 
Scheme 5. Preparation of Metalated 1 
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Similar to the other pentafluorophenyl corroles, 1, 1-Al, and 1-Ga exhibit bright 
fluorescence, particularly 1-Al, with a large Stokes shift.10  Excitation into the Soret or Q 
bands results in an emission spectral profile similar to that with lem observed around 600—
Figure 4. First row: Absorption (black), excitation (blue), and emission 
(red) spectra for 1 (a), 1-Al (d), and 1-Ga (g). Second row: 
Superimposed confocal fluorescence pseudocolor and bright-field 
images for 1−TiO2 (b), 1-Al−TiO2 (e), and 1-Ga−TiO2 (h). Third 
row: Fluorescence profiles of 1−TiO2 (c), 1-Al−TiO2 (f), and 1-Ga− 
TiO2 (i) aggregates with λex = 405 nm. The white circles represent the 
selected areas from which the corresponding spectral profiles were 
derived. 
 
Table 1. Electronic Spectroscopic Data for Chlorosulfonated Corroles 
1, 1-Al, and 1-Ga in Toluene Solutions 
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670 nm (Figure 1) accompanied by a vibronic band to the red of the major emission peak 
for the three corroles.  The excitation and emission wavelengths observed are set out in Table 
1.  We note that chlorosulfonated metallocorroles 1-Al and 1-Ga follow the expected trend 
for fluorescence in which lem (611 nm) for the slightly more electropositive 1-Al is more red-
shifted compared to lem (609 nm) for 1-Ga because of a destabilized highest occupied 
molecular orbital.11  The quantum yield measurements, relative to tetraphenylporphyrin,12 
with lex = 355 nm for 1, 1-Al, and 1-Ga reveal ϕem = 0.094, 0.127, and 0.099, respectively.  
As expected, the aluminum chlorosulfonated corrole exhibits the highest relative quantum 
yield, consistent with the previously reported relative quantum yield for the nonsulfonated 
aluminum(III) corrole.10b,c  The ϕem trend for all three chlorosulfonated corroles is 
comparable to that reported elsewhere for nonsulfonated comounds.10a-c 
On the basis of modification of the chlorosulfonyl group with alcohols producing 
sulfonic esters (13), we report the covalent modification of a chlorosulfonyl group with a 
new hydroxyl platform, namely, TiO2 NPs with hydroxylated surfaces, as an example of the 
versatility of chlorosulfonated corroles and their potential uses in optical imaging 
applications.  Corrole coupling to TiO2 NPs was performed following enhanced 
hydroxylation of the surface using H2O2.  The NPs bearing the hydroxylated surfaces were 
mixed with pyridine solutions of corrole and heated to reflux.  After repeated washing with 
copious amounts of CH2Cl2, acetone, and water and drying under high vacuum, green 
powders were obtained.  The electronic absorption spectra of the colloidal suspensions of 
1—TiO2, 1-Al—TiO2, and 1-Ga—TiO2 nanoconjugates in phosphate-buffered saline (pH 
7.4) reveal maximum absorptions centered around 425 and 600 nm for the Soret and Q bands, 
respectively (Table 2).  These peak maxima are in agreement with the spectroscopic 
properties of the corresponding molecular cororle (Table 1).  We also note that the Soret 
band splitting for 1—TiO2 is similar to the splitting observed for its amphiphilic molecular 
counterpart 2,17-disulfonato-5,10,15-tris-(pentafluorophenyl) corrole in an aqueous solution 
at physiological pH, supporting the presence of the sulfonate linkage on the corrole anchored 
to TiO2 surfaces.  The splitting pattern, however, is not observed for the metalloconjugates 
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1-Al—TiO2 and 1-Ga—TiO2, due to the presence of metal bound to deprotonated nitrogen 
atoms.10b-d,h 
 
Characterization of the fine green powder of 1—TiO2, 1-Al—TiO2, and 1-Ga—TiO2 
with Fourier transform infrared spectroscopy reveals vibrational absorption bands around 
1150—1250 cm-1 assigned to the symmetric stretching of SO2 groups as well as those around 
1400—1450 cm-1 assigned to asymmetric starching of SO2 groups of covalent sulfonates.14  
The presence of these vibrational signatures suggests that the corroles are covalently attached 
to the surface of TiO2 through a sulfonate linkage.  The vibrational frequencies for these 
TiO2—corrole nanoconjugates are listed in Table 2.  X-ray photoelectron spectroscopy was 
performed to study the elemental presence of the surface of the NP conjugates (Table 2).  
High-resolution scans for the spectra of the conjugates revealed F(1s) binding energy peaks 
between and 691 eV,15 suggesting the presence of corresponding 
(pentafluorophenyl)corroles attached to the TiO2 surface. 
Confocal fluorescence microscopy images of aggregates of the nanoconjugates 1—
TiO2, 1-Al—TiO2, and 1-Ga—TiO2 in the solid state (Figure 1) were taken with the samples 
illuminated at lex = 405 nm and lem recorded from 508 to 722 nm.  The images for 1-Al—
TiO2 and 1-Ga—TiO2 (Figure 1e,h) exhibit fluorescence areas on the NPs compared to the 
relatively darker image for 1—TiO2.  The fluorescence signals observed with various 
intensities across the TiO2 samples for 1-Al—TiO2 and 1-Ga—TiO2 also suggest that the 
Table 2. Electronic Absorption, Vibrational, and X-ray Photoelectron 
Spectroscopic Data for Corrole−TiO2 Nanoconjugates 1−TiO2, 1-
Al−TiO2, and 1-Ga−TiO2 
  
42 
TiO2 surfaces are not evenly functionalized because of material aggregation.  More 
detailed studies of the quenching of the fluorescence of 1—TiO2 are underway in our 
laboratories.  Upon closer inspection, however, of selected fluorescence areas (white circles) 
on all three images, spectral profiles representing the nanoconjugates 1—TiO2, 1-Al—TiO2, 
and 1-Ga—TiO2 were obtained (Figure 1c,f,i).  We note that these spectral profiles and 
fluorescence signal intensities are in agreement with the fluorescence spectra (Figures 1a,d,g) 
obtained from the molecular corroles 1, 1-Al, and 1-Ga.   
In summary, we have prepared TiO2 nanoconjugates whose surfaces were covalently 
modified with fluorescent chlorosulfonated corroles through sulfonic ester formation.  The 
nanoconjugate 1-Al—TiO2 exhibits the most intense fluorescence based on the spectral plot 
obtained from confocal fluorescence microscopy images.  This finding is in line with the 
fluorescence behavior (high relative ϕem) of 1-Al.  Further biological and imaging 
experiments involving these fluorescent nanoconjugates as potential contrast agents for 
optical imaging are underway in our laboratories.   
Acknowledgements 
We thank the CHLA Radiology Endowment Fund, Sanofi, and Doheny Eye Institute for 
financial support.  We thank Esteban Fernandez, George Rossman, Bruce Brunscwig, Zeev 
Gross, and Michael Lichterman for their help and discussion on this work.  We thank Mona 
Shahgholi (CCE Division Multiuser Mass Spectrometry Lab at Caltech) for her help with 
electrospray ionization mass spectrometry experiments. 
References 
(1) (a) Tempany, C. M.; McNeil, B. J. JAMA 2001, 285, 562. (b) Herschman, H. R. 
Science 2003, 302, 605. (c) Weissleder, R.; Pittet, M. J. Nature 2008, 452, 580. (d) 
Mura, S.; Couvreur, P. Adv. Drug Delivery Rev. 2012, 64, 1394. 
  
43 
(2) (a) Ntziachristos, V.; Ripoll, J.; Wang, L. V; Weissleder, R. Nat. Biotechnol. 2005, 
23, 313. (b) Borsook, D.; Becerra, L.; Hargreaves, R. Nat. Rev. Drug Discovery 2006, 
5, 411. 
(3) Willmann, J. K.; Van Bruggen, N.; Dinkelborg, L. M.; Gambhir, S. S. Nat. Rev. Drug 
Discovery 2008, 7, 591. 
(4) Winter, P. M.; Caruthers, S. D.; Kassner, A.; Harris, T. D.; Chinen, L. K.; Allen, J. 
S.; Lacy, E. K.; Zhang, H.; Robertson, J. D.; Wickline, S. A.; Lanza, G. M. Cancer 
Res. 2003, 5838. 
(5) (a) Endres, P. J.; Paunesku, T.; Vogt, S.; Meade, T. J.; Woloschak, G. E. J. Am. Chem. 
Soc. 2007, 129, 15760. (b) Xie, J. Inorg. Chem. 2008, 47, 5564. (c) Zhang, W.; Zhou, 
X.; Zhong, X. Inorg. Chem. 2012, 51, 3579. (d) Rodriguez-Liviano, S.; Becerro, A. 
I.; Alcantara, D.; Grazu,́ V.; De la Fuente, J. M.; Ocaña, M. Inorg. Chem. 2013, 52, 
647. 
(6) (a) Gross, Z.; Galili, N.; Saltsman, I. Angew. Chem., Int. Ed. 1999, 38, 1427. (b) 
Sankar, J.; Anand, V. G.; Venkatraman, S.; Rath, H.; Chandrashekar, T. K. Org. Lett. 
2002, 4, 4233. (c) Ngo, T. H.; Puntoriero, F.; Nastasi, F.; Robeyns, K.; Van Meervelt, 
L.; Campagna, S.; Dehaen, W.; Maes, W. Chem. Eur. J. 2010, 16, 5691. 
(7) (a) Mahammed, A.; Gray, H. B.; Weaver, J. J.; Sorasaenee, K.; Gross, Z. 
Bioconjugate Chem. 2004, 15, 738. (b) Li, C.-Y.; Zhang, X.-B.; Han, Z.-X.; 
Akermark, B.; Sun, L.; Shen, G.-L.; Yu, R.-Q. Analyst 2006, 131, 388. 
(8) (a) Agadjanian, H.; Weaver, J. J.; Mahammed, A.; Rentsendorj, A.; Bass, S.; Kim, 
J.; Dmochowski, I. J.; Margalit, R.; Gray, H. B.; Gross, Z.; Medina-Kauwe, L. K. 
Pharm. Res. 2006, 23, 367. (b) Agadjanian, H.; Ma, J.; Rentsendorj, A.; Valluripalli, 
V.; Hwang, J. Y.; Mahammed, A.; Farkas, D. L.; Gray, H. B.; Gross, Z.; Medina-
Kauwe, L. K. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 6105.  
  
44 
(9) (a) Mahammed, A.; Goldberg, I.; Gross, Z. Org. Lett. 2001, 3, 3443. (b) Saltsman, 
I.; Mahammed, A.; Goldberg, I.; Tkachecko, E.; Botoshansky, M.; Gross, Z. J. Am. 
Chem. Soc. 2002, 124, 7411. 
(10) (a) Bendix, J.; Dmochowski, I. J.; Gray, H. B.; Mahammed, A.; Simkhovich, L.; 
Gross, Z. Angew. Chem., Int. Ed. 2000, 112, 4214. (b) Mahammed, A.; Gross, Z. J. 
Inorg. Biochem. 2002, 88, 305. (c) Weaver, J. J.; Sorasaenee, K.; Sheikh, M.; 
Goldschmidt, R.; Tkachenko, E.; Gross, Z.; Gray, H. B. J. Porphyrins 
Phthalocyanines 2004, 08, 76. (d) Sorasaenee, K.; Taqavi, P.; Henling, L. M.; Gray, 
H. B.; Tkachenko, E.; Mahammed, A.; Gross, Z. J. Porphyrins Phthalocyanines 
2007, 11, 189. (e) Kowalska, D.; Liu, X.; Tripathy, U.; Mahammed, A.; Gross, Z.; 
Hirayama, S.; Steer, R. P. Inorg. Chem. 2009, 48, 2670. (f) Yang, Y.; Jones, D.; Von 
Haimberger, T.; Linke, M.; Wagnert, L.; Berg, A.; Levanon, H.; Zacarias, A.; 
Mahammed, A.; Gross, Z.; Heyne, K. J. Phys. Chem. A 2012, 116, 1023. (g) Ivanova, 
Y. B.; Savva, V. A.; Mamardashvili, N. Z.; Starukhin, A. S.; Ngo, T. H.; Dehaen, 
W.; Maes, W.; Kruk, M. M. J. Phys. Chem. A 2012, 116, 10683. (h) Kruk, M.; Ngo, 
T. H.; Savva, V.; Starukhin, A.; Dehaen, W.; Maes, W. J. Phys. Chem. A 2012, 116, 
10704. (i) Kruk, M.; Ngo, T. H.; Verstappen, P.; Starukhin, A.; Hofkens, J.; Dehaen, 
W.; Maes, W. J. Phys. Chem. A 2012, 116, 10695.  
(11) (a) Hush, N.; Dyke, J. Dalton Trans. 1974, 395. (b) Ghosh, A.; Wondimagegn, T.; 
Parusel, A. B. J. J. Am. Chem. Soc. 2000, 122, 5100. 
(12) Seybold, P. G.; Gouterman, M. J. Mol. Spectrosc. 1969, 31, 1. 
(13) Reynolds, D.; Kenyon, W. J. Am. Chem. Soc. 1950, 72, 1584. 
(14) Socrates, G. Infrared and Raman Characteristic Group Frequencies: Table and 
Charts; John Wiley & Sons: Chichester, U.K., 2001; p 218. 
(15) Barron, A. R., Ed. Physical Methods in Chemistry and Nano Science; Connexions: 
Houston, TX, 2012; p 365.  
  
45 
Supplementary Experimental 
Materials. 2 M AlMe3 in toluene (Aldrich), GaCl3 (Aldrich), HSO3Cl (Aldrich), 21 nm 
nanopowder TiO2 (Aldrich), 30% H2O2 (EMD) were obtained commercially and used as 
received. The starting material 5,10,15-tris(pentafluorophenyl) corrole (H3tpfc) was 
prepared based on the literature method.1 The solvents pyridine and toluene were dried over 
a column. Acetone and dichloromethane used were both of reagent and spectroscopic 
grades depending on the applications. 
Chemical Preparation. All preparations were carried out under Ar(g) atmosphere unless 
otherwise noted. 
1. Corrole Preparation. Preparation of 2,17-bischlorosulfonato-5,10,15-
tris(pentafluorophenyl) corrole (H3tpfc(SO2Cl)2; 1) was performed according to the 
literature procedure.2 The metallocorroles described in this study were prepared in the 
following manner. 
1.1. Preparation of 1-Al. To the 20-mL toluene solution of 0.32 g of 1 (0.32 mmol) 
in a round bottom flask was added 0.8 mL of 2 M AlMe3 (1.6 mmol) in toluene solution 
at an ice- bath temperature. The solution was stirred for 10 min followed by the addition 
of 1 mL anhydrous pyridine. The solution was allowed to stir for another 10 min over 
ice. The reaction was quenched by an addition of ice chips. The dark green solution was 
then extracted with CH2Cl2 and washed with water. The solvent was removed in vacuo 
and the dry deep green solid was redissolved in CH2Cl2 followed by filtration. The filtrate 
was brought to dryness to afford the dark green solid (0.098 g, 26% yield). ESI-MS 
(CH2Cl2): m/z: 1014.87 [M-H]- (Calculated for C37H6N4F15Cl2S2O4Al: 1015.88); 1H-
NMR (400 MHz, acetone-d6, ppm): d = 9.76 (s, 1 H), 9.25 (s, 1 H), 8.97 (d, 1 H), 8.85 
(d, 1 H), 8.70 (d, 1 H), 8.58 (d, 1 H); 19F-NMR (376 MHz, acetone-d6, ppm): -138.7 (d, 
4 F), -140.0 (d, 2 F), -156.9 (t, 1 F), -157.5 (t, 1 F), -158.1 (t, 1 F), -164.9 (m, 2 F), -165.3 
(m, 2 F), -167.0 (m, 2 F); UV-Vis (toluene:pyridine, 95:5): lmax (ε M-1 cm-1) = 436 (4.08 
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× 104), 625 (7.66 × 103) nm. 
1.2. Preparation of 1-Ga. To a heavy-walled Schlenk flask were added 0.20 g of 1 
(0.20 mmol) and 0.57 g GaCl3 (3.3 mmol) under Ar(g). The flask was chilled in N2(l) 
and evacuated. 15 mL Degassed anhydrous pyridine (15mL) was added to the flask via 
vacuum transfer. The flask was subsequently sealed and allowed to warm to room 
temperature. The reaction vessel was heated to 120 °C for 1 h. The pyridine solution 
was diluted with CH2Cl2 and washed with water three times. The solution was then 
filtered through glass wool and partially concentrated for recrystallization with hexanes 
overnight. The product was then filtered, dried, and washed with a combination of 
acetone, CH2Cl2, and toluene. This filtrate collected was brought to dryness in vacuo to 
afford a dark green solid (0.092 g, 38% yield). ESI-MS (CH2Cl2:pyridine): m/z: 1056.81 
[M-H]- (Calculated for C37H8N4F15Cl2S2O4Ga: 1057.82); 1H-NMR (500 MHz, CD2Cl2, 
ppm): d = 9.99 (s), 8.82 (m), 8.73 (m), 8.57 (m); 19F-NMR (376 MHz, acetone-d6, ppm): 
-138.7 (d), -140.0 (d), -156.9 (t), -157.5 (t), -158.1 (t), -164.9 (m), -165.3 (m), -167.0 
(m); UV-Vis (toluene:pyridine, 95:5): lmax (ε M-1 cm-1) = 429 (1.65 × 104), 611 (5.61 × 
103) nm. 
2. TiO2 Surface activation. To the solid TiO2 nanoparticle (10 g) in a 2.0-L round 
bottom flask was added 1.2 L 30% H2O2 solution. The milky colloidal suspension was 
stirred under reflux for 5 h. Upon cooling, the off-white solid was isolated from the 
H2O2 solution by ultra- centrifugation at 4 ºC and washed with copious amount of 
water. The activated TiO2 nano- particle (TiO2–OH) collected was dried in vacuo for 
12 h and stored dry in a vial prior to use. 
 
3. Surface Conjugation. The following general procedure was employed for the 
conjugation of the corroles 1, 1-Al, and 1-Ga to the activated TiO2 nanoparticle 
surface: To the mixed solids containing the activated TiO2 and corrole in a 25-mL 
round bottom flask was charged with anhydrous pyridine. The suspension turned green 
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immediately and was stirred under reflux before the reaction was stopped. The 
resulting green solid was isolated from the green solution by centrifugation and washed 
multiple times with dichloromethane, acetone, and deionized water until the centrifuge 
supernatant became colorless. The solid remained green, was dried in vacuo, and was 
stored until further use. The detailed preparation procedure for each corrole 
nanoconjugate is given as follows: 
3.1. Preparation of 1-TiO2. To a 25 mL round bottom flask were added 0.32 g TiO2 
OH and 0.028 g of 1 (28.1 µmol), which was subsequently cycled with argon and 
vacuum.  After establishment of the inert atmosphere, 8 mL anhydrous pyridine was added 
to the flask and the reaction was set to reflux for 2 h. The resulting green solid was 
collected in a manner following the general centrifugation and washing procedures 
outlined above. 
3.2. Preparation of 1-Al-TiO2. To a 40 mL vial was added 1.18 g TiO2–OH, which 
was subsequently cycled with argon and vacuum. To this flask, was added 5 mL 
anhydrous pyridine, followed by sonication to ensure even dispersion. In a second flask, 
was added 0.03 g of 1-Al (25.5 µmol) and 7 mL anhydrous pyridine under Ar(g).  This 
solution was stirred and then added to the TiO2–OH precursor via syringe. The reaction 
was sealed and allowed to reflux for 2 h after which, the resulting green solid was collected 
in a manner following the general centrifugation and washing procedures outlined above. 
3.3. Preparation of 1-Ga-TiO2. To a 40 mL vial was added 0.84 g TiO2–OH and 0.04 
g of 1- Ga (32.8 µmol), which was subsequently cycled with argon and vacuum.  After 
establishment of the inert atmosphere, 8 mL anhydrous pyridine was added to the flask 
and the reaction was set to reflux for 2 h. The resulting green solid was collected in a 
manner following the general centrifugation and washing procedures outlined above. 
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C h a p t e r  3  
CELLULAR UPTAKE AND CYTOTOXICITY OF A NEAR-IR 
FLUORESCENT CORROLE-TiO2 NANCONJUGATE 
As described in the previous chapter, we prepared and studied three corrole-
nanoconjugates—the freebase, gallium, and aluminum systems.  Based on initial confocal 
fluorescence microscopy of the conjugates and fluorescence quantum yield measurements of 
the unbound molecules, we identified the aluminum corrole naonconjugate as the brightest 
material, and therefore, the best possible candidate for optical imaging.  Our hypothesis, was 
that all things equal, the brightest system would be the best candidate as improved brightness 
would allow for better visualization during deep tissue imaging.   
The work described in this chapter required a lot of hands because of the extensive nature of 
the surface chemistry, microscopy, and biology involved.  Nonetheless, initial tests were 
promising.  An immortalized cell culture line, namely U87 glioblastoma, when treated 
appeared to uptake the nanoconjugate.  Based on these promising results we tested for 
toxicity.  We were pleasantly surprised that the conjugates exhibited very low levels of 
toxicity and that cells would proliferate even in the presence of fairly large quantities of the 
material.  The following pages describe our results, which we published in 2014. 
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Abstract: 
We are investigating the biological and biomedical imaging roles and impacts of fluorescent 
metallocorrole—TiO2 nanoconjugates as potential-near infrared optical contrast agents in 
vitro in cancer and normal cell lines.  The TiO2 nanoconjugate labeled with the small 
molecule 2,17-bis(chlorosulfonyl)-5,10,15-tris(pentafluorophenyl)corrolato aluminum (III) 
(1-Al—TiO2) was prepared.  The nanoparticle 1-Al—TiO2 was characterized by 
transmission electron microscopy (TEM) and integrating-sphere electronic absorption 
spectroscopy.  TEM images of three different samples of TiO2 nanoparticles (bare, H2O2 
etched, and 1-Al functionalized) showed similarity in shapes and sizes with an average 
diameter of 29 nm for 1-Al—TiO2.  Loading of 1-Al on the TiO2 surfaces was determined to 
be ca. 20-40 mg 1-Al/g TiO2.  Confocal fluorescence microscopy (CFM) studies of 
luciferase-transfected primary human glioblastoma U87-Luc cells treated with the 
nanoconjugate 1-Al—TiO2 as the contrast agent in various concentrations were performed.  
The CFM images revealed that 1-Al—TiO2 was found inside the cancer cells even at low 
doses (0.02—2 µg/mL) and localized in the cytosol.  Bioluminescence studies of the U87-
Luc cells exposed to various amounts of 1-Al—TiO2 showed minimal cytotoxic effects even 
at higher doses (2—2000 µg/mL) after 24 h.  A similar observation was made using primary 
mouse hepatocytes (PMH) treated with 1-Al—TiO2 at low doses (0.0003—3 µg/mL).  
Longer incubation times (after 48 and 72 h for U87-Luc) and higher doses (> 20 µg/mL 1-
Al—TiO2 for U87-Luc and > 3 µg/mL 1-Al—TiO2 for PMH) showed decreased cell 
viability.   
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1. Introduction 
Small molecules, biomolecules, and biocompatible materials for molecular imaging 
have played an important role in recent advances in biomedical and drug development 
research [1-3].  Application of contrast agents is required by many imaging modalities and 
allows for better understanding of biochemical pathways, physiological processes, and 
disease pathologies [4-8].  Many small molecules and biomolecules that function as 
molecular imaging contrast agents have been utilized in both preclinical and clinical settings 
[9].  Recent efforts have focused on nanomaterials, a start contrast to traditional small 
molecules and oligomers [10, 11].  Aside from the sizes of these materials, including volumes 
and surface areas, which essentially provide a canvas for numerous small molecule labeling, 
they exhibit properties not generally found in either bulk materials or discreet molecules [12-
14].  Examples of widely used and studied nanomaterials for biomedical imaging include 
quantum dots for optical imaging and superparamagnetic iron oxides for magnetic resonance 
imaging [10, 11]. 
In our work, we have employed semiconductor nanoparticulate titanium(IV) oxide 
(TiO2) covalently decorated with fluorescent corroles as a new class of optical imaging 
contrast agents for the study of cellular uptake and cytotoxic effects in cancer and normal 
cells.  TiO2, found in several different crystalline structures, such as rutile, anatase, and 
brookite, has been used in a number of contexts, including photocatalysis, dye-sensitized 
solar cells, and photochromic devices [15-19].  TiO2 nanoparticles exhibit a wealth of 
intrinsic properties dependent upon several factors, including surface area, crystalline phase, 
and single crystallinity.  We have exploited the facile nature with which the surface can be 
decorated with corroles, which were selected as optical dyes.  Many studies have shown that 
5,10,15-trispentafluorophenyl corrole and its derivatives exhibit bright and robust 
fluorescence signals in the near-IR region (lem > 600 nm) and are therefore considered 
suitable candidates for optical imaging [20-23].  In addition, the chemical versatility of 
corroles, allowing for various metalation [24-26] and substitution [27, 28] reactions, as well 
as their biological stability [29-31] makes them attractive contrast agents.   
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Previously we reported the syntheses, spectroscopic characterizations, and spectral 
confocal fluorescence imaging results for a family of corrole-TiO2 nanoconjugates, namely 
1—TiO2, 1-Al—TiO2, and 1-Ga—TiO2 [32].  The TiO2 nanoparticle surfaces were 
covalently labeled with chlorosulfonated corroles through a sulfonic ester linkage (Scheme 
1). 
Because 1-Al—TiO2 exhibits the brightest fluorescence, consistent with the emission 
properties of related molecular Al corroles [26, 32, 33], we chose this nanoconjugate as a 
model to study cellular uptake and cytotoxic effects.   
2. Experimental 
2.1 Reagents and materials 
Preparation of the Al(III)tpfc(SO2Cl)2 (1-Al) and the nanoconjugate 1-Al—TiO2 was 
reported previously [32].  D-Luciferin potassium salt (Promega), Hoechst 34580 
(Invitrogen™), Hoechst 33258 (Invitrogen™), Sytox Green (Invitrogen™), and FM® 1-
43FX (Invitrogen™) were used as received according to the provider’s instruction. 
2.2 Physical Methods 
Characterization of 1-Al was performed by 1H NMR, 19F NMR, electronic 
absorption, and fluorescence spectroscopies, and was reported previously [32].  Surface 
characterization of 1-Al—TiO2 is outlined as follows.   
Scheme 6. TiO2 surface labeling with 1-Al forming sulfonic ester 
linkages between the corrole and the surface. 
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2.2.1. Transmission electron microscopy 
The morphologies of the TiO2 nanoparticles before and after surface 
functionalization were imaged using an FEI Tecnai F30ST transmission electron microscope 
(TEM) operated at an acceleration voltage of 300 kV.  Images were recorded using a Gatan 
CCD camera.  For TEM analysis, a small quantity of TiO2 particles was dispersed in 
isopropyl alcohol (IPA) by sonication.  The dispersions were drop-cast onto C-flat™ holey 
carbon films on a 200 mesh Cu TEM grid (Electron Microscopy Sciences). 
2.2.2. Absorption spectroscopy 
Calculation of the corrole 1-Al’s loading on the surface of TiO2 was based on the 
absorbance values obtained from the integrating sphere electronic absorption measurements 
described as follows.   
Thin film transflectance measurements were used to determine 1-Al loading on the 
TiO2 nanoparticles. Both H2O2-etched and 1-Al-functionalized nanoparticles were dispersed 
in a polydimethylsiloxane (PDMS) polymer matrix. PDMS was chosen as it provides a 
transparent matrix for measuring the optical properties of porous solids [34]. The weights of 
the TiO2 nanoparticles, the PDMS base (Sylgard® 184 silicone elastomer base from Dow 
Corning), and the curing agent (Sylgard® 184 silicone elastomer curing agent from Dow 
Corning) are provided in Table A.1. The nanoparticles were first dispersed in a minimal 
amount of IPA by sonication. The dispersion of TiO2 nanoparticles in IPA was then mixed 
with the PDMS base and curing agent using a vortex mixer. The mixtures were cast into 
films onto quartz substrates and allowed to cure in air for 12 h followed by curing in a drying 
oven at 60° for 2 h. 
Transflectance spectra of the H2O2-etched and 1-Al-functionalized TiO2 nanoparticle 
films were measured using a Cary 5000 UV–vis-NIR spectrometer from Agilent 
Technologies equipped with an integrating sphere (External DRA 1800), a PMT detector, a 
quartz-iodine lamp for the visible region (350–800 nm), and a deuterium lamp for the ultravi- 
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olet region (300–350 nm). Because the TiO2 nanoparticles diffusely scattered the incident 
illumination, the PDMS films were placed in the center of the integrating sphere to collect 
both the transmitted, T, and the reflected, R, (including the spectrally reflected and diffusely 
scattered) light with the PMT detector. The transflectance measurements allowed for the 
absorbance, A, of the films to be determined by A = − log(T + R). The concentration, C, of 
1-Al within the PDMS films was then calculated using the Beer–Lambert law, A = εCl, where 
ε is the extinction coefficient of the dye and l is the film thickness (determined by 
profilometry, see below) [35–37]. The absorbance values at 426 and 595 nm (corresponding 
to the Soret and Q bands of the dye, respectively) for the PDMS film containing the 1-Al- 
functionalized TiO2 nanoparticles, the estimated extinction coefficients of 1-Al at these 
wavelengths, and the film thicknesses are provided in Table A.2. The absorbance values for 
the PDMS film containing the non-functionalized, H2O2-etched TiO2 nanoparticles at these 
wavelengths are also provided, which were subtracted from the absorbance values of the 1-
Al-functionalized TiO2 nanoparticles. The 1-Al-loading was determined to be 24 mg of 1-Al 
per gram of TiO2 based on the absorbance value of the Soret band and 38 mg of dye per gram 
of TiO2 based on the absorbance value of the Q band. 
Thickness profiles of the PDMS films were measured using a Bruker DektakXT 
stylus surface profilometer. The diameter of the diamond- tipped stylus was 2 µm and a 
weight of 1 mg was applied to the film. The stylus was scanned at a rate of 250 µm/s. The 
thickness profiles were used to measure the average path length through the PDMS films 
during the transflectance measurements. 
2.2.3. Hydrodynamic size and surface charge measurements 
The mean particle size was determined by dynamic light scattering (DLS, Malvern 
ZEN 3600 Zetasizer Nano) measurements. Samples of 1-Al–TiO2 suspended in PBS pH 7.2 
were pipetted into a low volume quartz cuvette with appropriate concentrations. At least nine 
measurements were performed for each sample. Each measurement comprised 20 runs with 
an average of 34,000 particle counts per second. The data represent the particle size 
distribution parameter, which reports the most frequent particle size in the sample accounting 
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for the intensity fluctuations of larger particles. The particle intensity was computed using 
Zetasizer Software version 7.01 applying the Stokes–Einstein equation to correlate the 
change in the scattering intensity and particle movements. Plots showing the average size of 
the nanoparticle aggregates are shown in Fig. A.1. The surface charge of 1-Al–TiO2 in PBS 
pH 7.2 was examined through ζ potential measurements (Malvern ZEN 3600 Zetasizer 
Nano). The average ζ potential was calculated from 20 measurements with 10–100 runs for 
each depending on the variation of the particles. 
2.3. Cell culture and cell viability assay 
Pathogen-free U87-LUC cell line (TSRI Small Animal Imaging and Research 
Laboratory) [38] was grown in a 75-mL flask in Dulbecco's Minimal Essential Medium 
(DMEM) in 5% CO2 at 37 °C. The cell culture medium was supplemented with 10% fetal 
bovine serum (FBS) and 1% antibiotic primocin. The cell culture medium was replenished 
every 2 days and the cells were passaged once they reached 80% confluence. Primary mouse 
hepatocytes (PMH) were isolated and cultured as previously described [39]. 
For U87-Luc cell culture experiments, cells plated in an 8-chamber slide (Nunc™ 
Lab-Tek™, Thermo Scientific) were treated with 1-Al–TiO2 suspended in PBS over a range 
of 0.002 µg/mL to 2000 µg/mL. A primary stock solution (6.3 mg 1-Al–TiO2 in 1 mL PBS) 
was prepared. The primary stock solution was further diluted to prepare secondary and 
tertiary stock solutions. Various amounts of stock solutions were added to the 8-chamber 
glass slide plated with cells to give the aforementioned range of concentrations. The final 
volume of each chamber was 300 µL. After treatment, the treated cells and controls were 
incubated in the dark in 5% CO2 at 37 °C for a period of 24, 48, and 72 h. The cells were 
imaged using a cooled IVIS® animal imaging system (Xenogen, Alameda, CA USA) linked 
to a PC running with Living Image™ software (Xenogen) along with IGOR (Wavemetrics, 
Seattle, WA, USA) under Microsoft® Windows® 2000. This system yielded high signal-to-
noise images of luciferase signals emerging from the cells. Before imaging, 20 µL of 5 
mg/mL luciferin in normal saline were added to each well. An integration time of 1 min with 
binning of 5 min was used for luminescent image acquisition. The signal intensity was 
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quantified as the flux of all detected photon counts within each well using the Living 
Image™ software package. All experiments were performed in triplicate. 
For PMH cell culture experiments, the cells were plated in a 6-chamber slide 
(Falcon®, Primaria™). After 3 h, media was exchanged (DMEM-F12) and the cells were 
treated with 1-Al–TiO2 suspended in PBS over a range of 0.0003 to 300 µg/mL. A primary 
stock solution (6.3 mg 1-Al–TiO2 in 1 mL PBS) was prepared. The primary stock solution 
was further diluted to prepare secondary and tertiary stock solutions. Various amounts of 
stock solutions were added to the 6-chamber glass slide plated with cells to give the 
aforementioned range of concentrations. The final volume of each chamber  was 2000 µL. 
After 24 or 48 h of treatment, cells were double stained with Hoechst 33258 (8 mg/mL) and 
Sytox Green (1 mM). Quantitation of total and necrotic cells (Sytox Green positive) was 
performed by counting cells in at least five different fields using ImageJ, as previously 
described [39]. All experiments were done in triplicate. 
2.4. In vitro confocal fluorescence microscopy 
The U87-Luc cells were seeded at 20,000 cells per well on an 8-chamber slide 
(Nunc™ Lab-Tek™, Thermo Scientific) and allowed to grow overnight. Cells were washed 
with PBS and were incubated in serum free media mixed 1:1 with 1-Al–TiO2 for 24, 48, and 
72 h at 37 °C over a concentration range similar to that of the U87-Luc cell viability assay 
(0.002 µg/mL to 2000 µg/mL). Cells were then washed 3 × with PBS and stained with 
Hoechst 33258 and FM® 1-43FX stains. The stained cells were kept chilled on ice without 
fixation until just prior to imaging. Z-stacked images were acquired with an LSM 710 con- 
focal system mounted on an AxioObserver Z.1 inverted microscope equipped with a 40 ×/1.2 
C-APOCHROMAT water-immersion lens (Carl Zeiss Microimaging, Thornwood, NY). 
Two visible laser lines of 405 and 488 nm were used for fluorescence excitation. The Z-
stacks were acquired with 0.5 µm slice intervals. The software ZEN 2010 was used for 
hardware control. To reduce blurring and noise in the raw images, they were processed with 
the 3D blind deconvolution algorithm of AutoQuant AutoDeblur software (Media 
Cybernetics, Silver Spring, MD) using the default settings for the laser scanning confocal 
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modality. ZEN and Fiji ImageJ software [40] were employed to further process the 
deconvolved images. 
3. Results and discussions 
3.1. Physical characterization of 1-Al—TiO2: TEM, DLS, and surface 
characterization 
TEM images of TiO2 (Fig. 1) were taken before and after H2O2-etching and surface 
functionalization. The images established that the average particle size post-corrole 
functionalization is 29 nm with a standard deviation of 7 nm. These results were obtained 
through averaging over 44 particles. Absorption measurements of the particles embedded in 
a transparent polymer matrix, facilitated with the use of an integrating sphere to distinguish 
between absorption and diffuse scattering by the nanoparticles, indicated nearly identical 
absorption features in the molecular and conjugated species. These experiments afforded an 
approximate loading of 1-Al on the surfaces of ca. 20–40 mg/g TiO2 (Fig. 2). 
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Figure 5. TEM images of TiO2 nanoparticles before and after dye-
functionalization.  Images of the initial TiO2 nanoparticles (a and d).  
Images of the nanoparticles after H2O2-etching (b and e).  Images of 
the nanoparticles after 1-Al functionalization (c and f).  The top scale 
bar refers to images a, b, and c and the bottom scale bar refers to 
images d, e, and f. 
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The hydrodynamic nature of 1-Al–TiO2 in PBS measured by the DLS method 
revealed great heterogeneity in size of the aggregates. While the average size of 1-Al–TiO2 
in PBS was measured to be 200 nm in diameter, smaller and larger aggregates were observed. 
In addition, zeta (ζ) potential measurements of 1-Al–TiO2 in PBS exhibited moderate 
stability and revealed a negatively charged surface with a ζ potential of − 27.4 (±1.25) mV 
at the concentration of 50 µg/mL. 
3.2. Confocal fluorescence microscopy and uptake of 1-Al—TiO2 by U87-Luc cells 
Figure 6. Absorbance spectra of H2O2-etched TiO2 nanoparticles 
embedded in a PDMS polymer matrix before (blue, dashed line) and 
after 1-Al functionalization (red, solid line), as well as the absorption 
spectrum of PDMS on quartz (black, dotted line). The absorption 
spectra were measured in transflectance mode where both transmitted 
and reflected light were collected employing an integrating sphere.  
  
60 
Treatment of the luciferase-transfected glioblastoma cell U87-Luc with a wide 
range of 1-Al–TiO2 concentrations revealed internalization of these nanoconjugates over a 
period of 24, 48, and 72 h as shown by CFM (Fig. 3). We also show the Z-stacked three-
dimensional CFM images (Fig. 4) of U87-Luc cells treated with 0.02 µg/mL of 1-Al–TiO2 
for 48 and 72 h from three different perspectives. 
Figure 7. CFM images of U87-Luc cells incubated with 0.02 µg/mL 
1-Al—TiO2 (red) for 24 h (a), 48 h (b), and 72 h (c) and stained with 
dyes to mark the membrane (green) and nucleus (blue). 
Figure 8. Z-Stacked CFM images of individual U87-Luc cells taken at 
0.5 um z-slice intervals from top to bottom after (a) 48 h and (b) 72 h 
of treatment with 0.02 µg/ml 1-Al—TiO2. 
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The CFM images were taken after the cells were stained with nuclear and cell 
membrane dyes, and washed with media solution several times to remove unbound dyes and 
1-Al–TiO2 nanoconjugates. The nucleus labeled with a Hoechst stain is colored blue (λex = 
405; λem = 460 nm), the membrane labeled with the dye FM® 1-43FX is colored green (λex 
= 488; λem = 580 nm), and the nanoconjugate 1-Al–TiO2 is colored red (λex = 405; λem = 634 
nm). 
While mechanisms of 1-Al–TiO2 uptake and localization into cells will be studied 
further, we propose that the 1-Al–TiO2 nanoconstruct is internalized through endocytosis, 
consistent with previous work [41–46]. We note that, based on confocal fluorescence 
imaging, the nanomaterial 1-Al–modified TiO2 appears to be suspended in the cytosol. This 
finding is consistent with the distribution pattern of TiO2 nanoconjugates in HeLa cells in a 
previous study of 1D TiO2 nanorods and nanoparticles labeled with fluorescein thiocyanate 
[43]. However, modified TiO2 labeled with alizarin red S has been shown to have perinuclear 
localization in HeLa cells, in contrast to our observations with 1-Al–TiO2 [41,42]. Recent 
studies involving uptake of other modified TiO2 nanoparticles in various cell lines, such as 
mouse fibroblasts and osteoblasts, suggested cellular internalization and distribution of TiO2 
nanoparticles at the endosome/lysosome and in the cytoplasm, in accord with our findings 
[44,45]. We note that internalization of 1-Al–TiO2 into glioblastoma cells can be observed 
at very low concentrations (0.02–2 µg/mL). 
3.3. Cytotoxicity in U87-Luc cells 
It is well documented that TiO2 nanoparticles exhibit various degrees of cytotoxic 
activity upon photoactivation by UV–vis light due to formation of reactive oxygen species 
[43,44,46]. A study of water-soluble single-crystalline TiO2 nanoparticles in melanoma A-
375 cells revealed that in the absence of UV light the TiO2 nanoparticles were essentially 
non-toxic and thus biocompatible [46]. However, upon irradiating these cells with UV light 
less than 20% of the melanoma cells survived at a TiO2 concentration of 400 µg/mL. 
Therefore, in an attempt to understand the cytotoxic effects of the 1-Al–TiO2 conjugate 
independently of its phototoxic properties, we treated the glioblastoma cell U87-Luc in the 
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absence of UV–vis irradiation with the same range of 1-Al–TiO2 concentrations as in the 
cell internalization studies (0.002– 2000 µg/mL). The cells were incubated over a period of 
24, 48, and 72 h prior to bioluminescence cell viability assays [38,47]. Based on the bio- 
luminescence signal of the firefly luciferin from living U87-Luc cells, which is related to the 
level of cellular ATP, the cytotoxic assay showed that the nanoconjugate 1-Al–TiO2 had 
essentially no cytotoxic effect on the glioblastoma cells after 24 h of treatment (Fig. 5) and, 
therefore, could be considered biocompatible. The cytotoxic effect became more apparent as 
the cells were exposed to the corrole–TiO2 nanoparticles for extended periods of time at 
higher concentrations (> 200 µg/mL). For example, only ca. 65% and ca. 30% of the 
bioluminescence signal from the live cells was observed after 48 h and 72 h treatments at 
2000 µg/mL, respectively. Our viability study of the U87-Luc cells treated with 1-Al–TiO2 
was also consistent with a study performed on mouse fibroblast cells, using the MTT assay, 
showing that the cytotoxic effects of TiO2 at various concentrations (3–600 µg/mL) were 
negligible after 24 h of treatment, whereas the 48 h treatment of these cells with the 
nanoparticle showed a decrease in cell viability at higher concentrations [44]. Another study 
Figure 9. Cell viability plot of U87-Luc cells treated by 1-Al–TiO2 at 
various concentrations (0.002–2000 µg/mL) using a bioluminescence 
assay. 
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on the cytotoxicity effect of unmodified 1D and 3D TiO2 nanostructures on HeLa cells 
also showed that these nanoparticles were relatively nontoxic at concentrations up to 125 
µg/mL in the absence of light [43]. 
3.4 Cytotoxicity in primary mouse hepatocytes 
Additionally, to determine the cytotoxic effect of the nanoconjugate 1-Al–TiO2 on 
non-cancerous cells, we treated primary mouse hepatocytes (PMH) with 1-Al–TiO2 at 
various concentrations (0.0003–300 µg/mL) for 24 and 48 h (Fig. 6) in the absence of UV–
vis irradiation. Similar to the results observed for cancerous U87-Luc cells, 1-Al–TiO2 was 
essentially nontoxic in non-cancerous PMH at up to 3 µg/mL after both 24 and 48 h of 
treatment. Only at higher concentrations did the proportion of the live PMH drop below 80%. 
We note that the PMH behaved similarly after 24 h and 48 h treatments with various doses 
of 1-Al–TiO2, suggesting that low 1-Al–TiO2 concentrations had minimal cytotoxic effects 
on the viability of these non-cancerous cells. The PMH were more susceptible to the 
cytotoxic effects of 1-Al–TiO2 than the U87-Luc cells; it is reasonable that non-cancerous 
cells, especially primary cells, would be less tolerant towards exogenous non-native agents 
[48,49]. Nonetheless, the intense fluorescence exhibited by 1-Al [26,33] would allow for the 
potential use of the nanoconjugate 1-Al–TiO2 as an optical imaging agent observable by 
confocal fluorescence microscopy even at low concentrations (0.02–2 µg/mL) below the 
cytotoxic thresholds for both cancerous and non-cancerous cells. 
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4. Conclusions 
In summary, we report detailed characterization of 1-Al–TiO2, a nanoconjugate that 
potentially could be used as a metal oxide nanoprobe for optical imaging, owing to intense 
fluorescence as well as its biocompatibility. The biological studies suggest that 1-Al–TiO2 is 
essentially nontoxic at concentrations up to 3 and 2000 µg/mL for normal mouse liver cells 
and glioblastoma U87-Luc cells, respectively, within the first 24 h of treatment. The PMH 
viability, however, dropped at higher concentrations (> 3 µg/mL) after 24 h and 48 h 
treatments and the U87-Luc cell viability also declined at higher concentrations (> 20 µg/mL) 
after 48 h and 72 h treatments. We also would like to note, for example, that comparable to 
our PMH cytotoxic assay over the concentration range for 1-Al–TiO2 of 0.0003–300 µg/mL, 
superparamagnetic iron oxide nanoparticle used in MRI was studied for their cytotoxicity in 
Figure 10. Cell viability plot of PMH treated with 1-Al–TiO2 at 
various concentrations (0.0003– 300 µg/mL) using a Syntox Green 
live-dead assay. 
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fetal stem cell lines over a low concentration range (5–35 µg/mL) [50]. Another example 
includes PDMAEMA-modified ZnO QDs functioning as contrast agents in monkey kidney 
cells over a concentration range of 50–800 µg/mL [51]. More importantly, our CFM studies 
demonstrated that the nanoconjugate 1-Al–TiO2 was internalized in U87-Luc cells even at a 
relatively low concentration (0.02 µg/mL). Although further detailed localization and 
internalization mechanism studies should be performed, our current work has revealed that 
there is random suspension of 1-Al–TiO2 in the cytosol even after 72 h treatment. Notably, 
the observation of near-IR fluorescence of 1-Al–TiO2 over a non-toxic concentration range 
(0.002–2000 µg/mL) in U87-Luc after 24 h treatment suggests that corrole–TiO2 
nanoconjugates could be very promising candidates for use as biological imaging agents. 
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Supplementary Materials 
Table A.1 Masses of TiO2 nanoparticles, IPA, the PDMS base, and curing agent used to cast 
PDMS films, weight % TiO2 in the films, film weight, and mass of TiO2 per volume of 
PDMS. 
 
Sample Mass 
TiO2 
(mg) 
Mass 
IPA 
(g) 
Mass 
PDMS 
base (g) 
Mass 
PDMS 
curing 
agent (g) 
Total 
weight 
(g) 
Est. 
dry 
weight 
(g)a 
Weight 
% TiO2 
Film 
weight 
(g) 
Mass TiO2 
/volume 
PDMS 
(g/L)b 
Etched 
TiO2 
3.25 0.3234 0.9425 0.1154 1.3846 1.0676 0.30 0.2901 3.2 
1-Al-TiO2 3.35 0.3683 0.9266 0.1220 1.4203 1.0593 0.32 0.2914 3.3 
a Separate measurements showed that 98% of the IPA evaporated during curing of the PDMS 
film. 
b A value of 0.965 g/cm3 was used for the density of PDMS. 
 
 
Table A.2 Absorption values at 426 and 595 nm and thicknesses for PDMS films containing 
1-Al-functionalized and H2O2-etched TiO2 nanoparticles, and estimated 1-Al loading of the 
TiO2 particles based on absorption measurements. 
 
Wavelength 
(nm) 
1-Al-
functionalized 
TiO2 
absorbance 
Film 
thickness 
(cm) 
Est. dye 
extinction 
coefficient 
(M-1cm-1)a 
Etched 
TiO2 
absorbance 
Film 
thickness 
(cm) 
1-Al 
concentration 
(M) 
1-Al 
loading 
(mg of 
dye/g of 
TiO2) 
426 0.170 0.054 4.08´104 0.005 0.054 7.5´10-5 23 
595 0.048 0.054 7.66´103 0.002 0.054 1.2´10-4 36 
a Extinction coefficients measured in toluene:pyridine (95:5) mixture where the Soret band 
has an absorption maximum at 436 nm and the Q band has an absorption maximum at 625 
nm.  
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C h a p t e r  4  
DRUG CAPTURE MATERIALS BASED ON GENOMIC DNA-
FUNCTIONALIZED MAGNETIC NANOPARTICLES 
The final chapter of my thesis is taken from a manuscript that we (my collaborators and I) 
intend to submit for review and publication around the time of my defense.  This project 
originated from a conversation with a few MDs during a Caltech-UCSF consortium meeting.  
Mariam Aboian and Caroline Jordan presented work from the Hetts group in the Department 
of Interventional Radiology at UCSF.  These doctors discussed an idea that seemed 
outlandish in principle but completely useful in practice.  They wanted to make 
chemotherapy regimens less toxic.  The Hetts group insisted that by removing 
chemotherapeutic drugs from the bloodstream after the site of activity, systemic toxicity 
could be reduced—that meant patients would not be nearly as sick from therapy, improving 
adherence and prognosis. 
The Hetts group shared that they were using DNA as a filtration medium for removing DNA 
targeting drugs including doxorubicin.  The problem they experienced was with device 
construction.  With my background in surface functionalization, I suggested we investigate 
the use of synthetic DNA on the surface of nanoparticles to help structure devices that could 
be coated.  Little did I know that synthetic DNA could truly be as expensive as I found it to 
be.  More than that, synthetic DNA took months to get our hands on, at least at the scale we 
needed to make nanoparticle functionalized materials.   
Nonetheless, a synthetic approach worked for drug capture, but marginally, and cost dictated 
that the technology would not be scalable.  Bob and I met to discuss results, at which point 
we thought about using commercially available genomic DNA.  It was cheap and abundant 
but nearly impossible to do chemistry with.  After enough brainstorming, we concluded that 
the only types of chemistry we could do on DNA were crosslinking and alkylating, in line 
with modern chemotherapeutics.  So that was what I did.  I prepared what I thought to be an 
analogue to cisplatin on the surface of iron-oxide using silane linkages bearing diamines.  
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When reacted with DNA derived from herring, the platinum complex reacted affording a 
DNA coated nanoparticle.  Additional thought went into other methods and we concluded 
that multi-arm nitrogen mustards would be even more reactive than the platinum 
species…and they were cheaper!   
Michael Schulz, a truly wonderful postdoc, joined in on the project not long after.  He helped 
devise many of the studies we used to evaluate the efficacy of our materials.  The project 
started to pick up traction and after a few months we saw efficacy for drug capture even in 
whole porcine blood.  Nonetheless, the following chapter details the synthesis and evaluation 
of drug capture materials based on the genomic DNA covalent functionalization of metal-
oxide surfaces.   
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DRUG CAPTURE MATERIALS BASED ON GENOMIC DNA-
FUNCTIONALIZED MAGNETIC NANOPARTICLES 
Authors: Carl M. Blumenfeld†, Michael D. Schulz†, Mariam S Aboian, Mark W. Wilson, 
Terilyn Moore, Steven W. Hetts, Robert H. Grubbs* 
 
One Sentence Summary: Iron-oxide nanoparticles were functionalized with genomic DNA 
and used to sequester doxorubicin and other chemotherapy agents from biological solutions 
both in vivo and in vitro.  
Abstract: Chemotherapy agents are notorious for producing severe side-effects. One 
approach to mitigating this off-target damage is to deliver the chemotherapy directly to a 
tumor via transarterial infusion, or similar procedures, and then sequestering any 
chemotherapeutic that enters systemic circulation. Materials capable of such drug capture 
have yet to be fully realized. We report the first covalent attachment of genomic DNA to 
surfaces (iron-oxide nanoparticles). With these magnetic materials, we captured three 
common chemotherapy agents—doxorubicin, cisplatin, and epirubicin—from biological 
solutions. We achieved >80% capture of doxorubicin from human serum in 1 minute, with 
98% capture in 10 minutes, all at physiologically relevant concentrations. Finally, the in vivo 
efficacy of these materials was demonstrated in a porcine model, which showed an 82% 
reduction in doxorubicin concentration over the length of a particle-coated device. The 
efficacy of these materials indicates that drug capture is a viable strategy for mitigating 
chemotherapy-associated side-effects. 
The systemic toxicity of chemotherapy is a widely recognized problem in oncology. 
Off-target damage often persists indefinitely, adversely affects patient survival, and restricts 
dose and treatment options.1,2 Direct administration of chemotherapy agents to the tumor via 
transarterial chemoembolization, or similar procedures, followed by sequestration of any 
chemotherapeutic that enters systemic circulation would mitigate this damage if materials 
capable of such drug capture were fully realized.3,4 
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Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths 
worldwide.5 Liver transplantation is the most definitive approach for treatment; however, 
less than 30% of HCC patients are eligible.6 Direct delivery of drug to a tumor via 
intraarterial chemotherapy (IAC) and its variant, transarterial chemoembolization (TACE), 
is often used as a bridge to transplantation, shrinking HCC or at least controlling its growth 
through recurrent treatments until curative transplant is possible. In cases where surgery is 
untenable, chemotherapy is often the only recourse. Targeted therapy, however, does not 
completely eliminate side-effects.  
Three of the most common drugs used to treat HCC are doxorubicin (DOX), 
epirubicin (EPI), and cisplatin (Fig. 1c), all of which act on DNA.7 DOX and EPI function 
by intercalating between DNA base pairs, while cisplatin is a DNA crosslinker that functions 
by binding to guanine.8,9 A major problem for these anticancer compounds is toxicity in non-
targeted tissues. DOX and EPI toxicity can result in cardiomyopathy and congestive heart 
failure.8–10 Similarly, cisplatin elicits side-effects including extensive nephrotoxicity and 
neurotoxicity.11,12 To reduce the likelihood of cardiac toxicity, cumulative dosage of DOX is 
generally limited by clinicians to 400-450 mg/m2, though lower cumulative dosages (300 
mg/m2) are known to increase the risk of congestive heart failure.13,14 Still, a single standard 
dose of DOX (50-75mg) can result in severe side-effects, yet higher dosages of DOX are 
known to be associated with greater tumor suppression. Consequently, a balance must be 
struck in order to maximize drug dose, leading to better tumor suppression, while 
simultaneously avoiding catastrophic off-target toxicity. Although limiting a patient’s 
lifetime cumulative dose is the most effective way to avoid cardiotoxicity, this approach 
necessarily limits anti-cancer efficacy.15 
The unwanted systemic toxicity of chemotherapy agents has inspired a number of 
more targeted approaches. One such approach is TACE, during which liver blood flow is 
occluded in conjunction with administration of high dose chemotherapy directly to the 
tumor.3,16 Both during TACE and after liver blood flow is restored, however, up to 50% of 
residual chemotherapeutics enter systemic circulation and cause off-target toxicity.17  
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Efforts have been made toward reducing non-targeted toxicity during TACE. In 
2014 Patel and coworkers proposed chemotherapy filtration devices (“ChemoFilters”) that 
employed sulfonated ion-exchange resins with affinity for DOX. Such a device could be 
deployed via catheter in the hepatic vein, “downstream” from the site of chemotherapy 
administration, where it can intercept any residual chemotherapy agents before they reach 
the heart and enter systemic circulation. They demonstrated a 52% reduction in DOX 
concentration from porcine serum over 10 minutes, and showed that such a device could be 
successfully deployed during a simulated TACE procedure.3 In 2016, the “ChemoFilter” 
approach inspired the development of more elaborate block copolymer membranes for DOX 
capture, which achieved up to 90% removal of DOX in 31 minutes from phosphate buffered 
saline (PBS).4  
Inspired by the ChemoFilter concept, we designed and synthesized DNA-
functionalized materials based on magnetite (Fe3O4) nanoparticles, capable of rapidly 
capturing chemotherapy agents. Central to our approach is the direct covalent attachment of 
genomic DNA. Functionalizing surfaces with DNA has historically involved tagging either 
the backbone or bases of synthetic DNA with an appropriate moiety, or attaching the DNA 
via a reactive end-group. These approaches are highly useful and enable complete control of 
the DNA sequence used resulting in the development of numerous interesting materials;18–25 
however, they are limited by the relatively high cost of synthetic DNA. The synthesis of large 
amounts of such materials would be prohibitively expensive for most applications.  
Functionalization with genomic DNA is an alternative approach that may be 
appropriate for certain applications; however, this approach is relatively unexplored. Pierre 
and coworkers recently synthesized magnetic nanoparticles with surface-bound intercalating 
groups, and showed that such materials can bind to genomic DNA.26 To our knowledge, 
however, no one has reported the covalent attachment of genomic DNA to a surface. Here, 
we report two methods of attaching genomic DNA to nanoparticles, both on multi-gram scale 
(Fig. 1a). We show that the resulting materials are capable of removing DNA-targeting 
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chemotherapy agents from solution both rapidly and in the presence of potential biological 
intereferents (e.g., serum proteins and other blood components). 
DNA-alkylating agents are a common motif in chemotherapy. By forming covalent 
crosslinks between DNA strands, these drugs prevent the DNA from being accurately 
duplicated, ultimately leading to apoptosis. To attach genomic DNA to magnetic 
nanoparticles, we used an approach analogous to DNA-alkylating/crosslinking drugs (Fig. 
1a). The first approach was inspired by cisplatin. To synthesize IONP-Pt-DNA samples, the 
hydroxylated surface of magnetite was silylated with N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane exposing a chelating diamine functionality. This sample was 
treated with an excess of potassium tetrachloroplatinate to create an analogue of cisplatin by 
which DNA could be anchored to the surface. Cisplatin’s cytotoxicity is thought to stem from 
its coordination with nucleophilic N7-sites of purine bases, resulting in crosslinks.27 We 
hoped to accomplish DNA crosslinking to the surface through this mechanism. The sample 
was then exposed to DNA to produce IONP-Pt-DNA.  
The second approach was modeled on nitrogen mustard chemotherapy agents. IONP-
HN3-DNA samples were prepared first by functionalizing magnetite with 4-
aminobutyltriethoxysilane to install free amines on the surface. This particle was then treated 
with excess tris(2-chloroethyl)amine hydrochloride (HN3•HCl) to create a scaffold for DNA 
functionalization. HN3•HCl, the hydrochloride salt of the nitrogen mustard HN3, undergoes 
aziridinium formation when deprotonated, and is attacked readily by the nucleophilic 
moieties of DNA.28 The functionalized particle was exposed to DNA resulting in IONP-
HN3-DNA. Both materials were characterized by scanning electron microscopy, electron 
dispersive scattering, elemental analysis, and infrared spectroscopy (see Supplementary 
Information). 
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In order to evaluate the efficacy of our materials at scavenging chemotherapy agents 
from solution we studied DOX-binding in human serum at 37 °C to approximate the 
biological environment in which these materials would have to operate. We found that IONP-
HN3-DNA was able to capture 93% of DOX, on average, from a 0.05 mg/mL solution in 25 
minutes, while IONP-Pt-DNA averaged 79% (Fig. 2a). In both cases, the kinetics were 
extremely rapid, with about 50% of DOX capture occurring within one minute in the case of 
IONP-Pt-DNA and over 65% DOX capture occurring within one minute for IONP-HN3-
DNA. Based on these results, we carried out all further tests with IONP-HN3-DNA. 
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Figure 11: a. Two synthetic approaches for covalently mounting 
genomic DNA onto iron-oxide nanoparticle (IONP) surfaces. b. 
Drug capture concept. c. Three common chemotherapy agents used 
in this study. 
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Interestingly, both materials were highly effective, despite the known binding of 
DOX with serum albumin. It is known that DNA intercalation is the kinetically more 
favorable process,29,30 and we believe that this kinetic advantage enabled our material to 
capture DOX from serum solution, despite the thermodynamics being in favor of serum 
binding overall. We posit that over longer timescales, serum binding would be the dominant 
process; however, since TACE is a relatively short procedure (<1 h), we believe that kinetic 
factors will dominate in the performance of any material or device.  
Drug capture was also evaluated in porcine whole blood, by measuring DOX plasma 
concentration over time. We observed some DOX removal due to binding to the non-plasma 
blood components, which we cannot deconvolute from capture by our materials. 
Nevertheless, there is rapid reduction of DOX concentration in the blood plasma within 1 
minute after exposure to our material, reaching a 92% reduction in DOX plasma 
concentration over 10 minutes, in stark contrast to the control experiment (Fig. 2b). This 
experiment conclusively demonstrates that our materials are capable of capturing DOX from 
whole blood. 
Figure 12: Decrease in DOX concentration in human serum, 
determined by fluorescence, as a result of DOX capture by IONP-
HN3-DNA and IONP-Pt-DNA; 100±5 mg particle in 20 mL (0.05 
mg/mL), 1 mg total DOX, 37 °C; error bars = 1 standard deviation 
(n=3). b. Decrease in DOX plasma concentration as a result of DOX 
capture by IONP-HN3-DNA  from porcine whole blood; 100±5 mg 
IONP-HN3-DNA in 20 mL (0.05 mg/mL), 1 mg total DOX, 37 °C; 
error bars = 1 standard deviation (n=3). 
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To better understand the DOX-capture capacity of IONP-HN3-DNA, we 
performed a series of experiments in which nanoparticle loading was systematically varied 
(Fig. 3a, further data in the Supplementary Information). These experiments revealed a 
roughly linear trend in DOX-capture as a function of the amount of particle added, up to a 
plateau around 100 mg material added per mg DOX, resulting in ~90% DOX capture in 10 
minutes. Further DOX capture appears less favorable after this point. We believe this plateau 
is the result of competition with serum binding, which makes that portion of DOX 
unavailable for capture by our particles, as well as the typical kinetic effects of diminishing 
concentration. The absorption of DOX onto the particles was further verified by performing 
confocal fluorescence microscopy (Fig. 3b and Fig. 3c). This technique allowed 
visualization of the fluorescence of DOX bound to the surface of the particles.  
Our approach is general for all DNA-targeting chemotherapy agents. To demonstrate 
this fact, we performed further experiments on two additional common DNA-targeting 
chemotherapeutics: cisplatin and EPI. We performed an initial cisplatin-binding experiment 
in PBS solution with IONP-HN3-DNA and monitored the decrease of cisplatin concentration 
by inductively coupled plasma-mass spectrometry. Approximately 20% of the cisplatin was 
captured from solution over 30 minutes, with little improvement over longer time periods 
(see Supplementary Information). We confirmed the presence of captured cisplatin on the 
surface of the particles by x-ray photoelectron spectroscopy.  
Along with DOX and cisplatin, EPI is among the most commonly used 
chemotherapeutic agents for treating HCC. We evaluated the efficacy of our materials for 
capturing EPI using a set of experiments analogous to those we used with DOX (see 
Supplementary Information). Our particles were highly effective at sequestering EPI from 
serum, with 68% captured after 25 minutes. The sequestered amount would lead to a 
reduction in unwanted side-effects if achieved in vivo. 
  
  
80 
 
A device (Fig. 4a) consisting of IONP-HN3-DNA magnetically adhered to the surface of 
cylindrical rare-earth magnets strung along a PTFE coated nitinol wire was evaluated using 
a closed loop flow model3 (see Supplementary Information) and subsequently tested in vivo 
using a porcine model. The device was inserted into the inferior vena cava (IVC) and DOX 
Figure 13: a. DOX capture as a function of the amount of IONP-
HN3-DNA from a DOX  serum solution (0.5 mg total DOX, 0.05 
mg/mL); average of three experiments, data set with error bars in 
Supplementary Information. b. Resulting serum solutions from 
experiments summarized in (a). c. Brightfield image of IONP-HN3-
DNA aggregates bound to DOX. d. Fluorescence from DOX bound 
to IONP-HN3-DNA. 
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was injected over ten minutes into the left common iliac vein proximal to the device (Fig. 
4b). As the drug flowed through the inferior vena cava, it made contact with the bound IONP-
HN3-DNA and was captured. Blood aliquots were taken proximal to, adjacent to the 
midpoint of, and distal to the device using separate catheters. Peak drug concentration was 
observed at three minutes since the blood at the injection site had recirculated and live 
injection was still underway. At peak concentration, a 60% reduction in serum DOX 
concentration was observed half-way across the device, while a total reduction of 82% was 
observed at the end of the device (Fig. 4c,d). 
 
 
Figure 14: a. Device containing 25 magnets (1 cm x 0.5 cm) with 
IONP-HN3-DNA coating (above), and the same device after the in 
vivo experiment (below), demonstrating minimal loss of particles after 
removal of the device.  b. Fluoroscopy images during in vivo porcine 
experiment demonstrating the inferior vena cava with opacified right 
renal veins.  The device was placed within the inferior vena cava.  The 
sampling catheters were placed immediately proximal to the device, 
prior to the renal vein, and distal to the device.  c. DOX concentration 
measurements from pre-device, mid-device, post-device, and 
peripheral locations. d. Plasma solutions from the experiment 
described in (c). 
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We have demonstrated two viable synthetic pathways to genomic DNA-
functionalized magnetic particles, both on multi-gram scale. To the best of our knowledge, 
this is the first report of a functional material synthesized with genomic DNA. Moreover, 
these novel methodologies for DNA surface functionalization are not limited to magnetic 
metal-oxides, but may also be exploited for other substrates. The synthesized materials 
captured three commonly used chemotherapy agents from relevant biological solutions 
(PBS, human serum, or porcine whole blood), at therapeutically relevant concentrations and 
timescales. This approach is the first to demonstrate such high efficacy and versatility. A 
proof of concept device was developed, which demonstrated efficient capture of doxorubicin 
in vivo. Similar devices could be readily developed that would reduce the off-target toxicity 
and damaging side-effects associated with the use of doxorubicin, cisplatin, and epirubicin 
during TACE or similar procedures. Ultimately, we believe our approach is general for all 
DNA-targeting chemotherapy drugs, and we hope that this work will provide a foundation 
for further work on DNA-based materials and drug capture approaches both for oncologic 
and non-oncologic applications. 
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Supplementary Information: 
Materials and Methods:  
Instrumentation: Fluorescence measurements were made using a 96-well plate on a 
Molecular Devices FlexStation 3 Multi-mode microplate reader. Scanning electron 
micrographs (SEM) as well as electron dispersive scattering (EDS) measurements were 
made on a Zeiss 1550VP Field Emission SEM equipped with an Oxford EDS module. 
Inductively coupled plasma-mass spectrometry (ICP-MS) was carried out on an HP 4500 
ICP-MS equipped with a Cetac ASX-500 autosampler. Infrared measurements were made 
on a Nicolet iS50 Fourier Transform Infrared spectrometer equipped with a DuraScope ATR 
unit. C, H, N analyses were carried out using a PerkinElmer 2400 Series II CHN Elemental 
Analyzer. 
General Procedures: Unless otherwise stated reactions were carried out on the bench. 
Magnetite (Fe3O4, 40 nm APS, 99%) was purchased from Nanostructured & Amorphous 
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Materials, Inc. Silane reagents were purchased from Gelest, Inc. Genomic DNA (isolated 
from Herring sperm), human serum (OptiClear), and cisplatin were purchased from Sigma 
Aldrich. Doxorubicin was purchased from LC Labs and epirubicin was purchased from 
Biotang Inc. Potassium tetrachloroplatinate was purchased from Pressure Chemicals. All 
reagents not otherwise mentioned were purchased from Sigma Aldrich, and were used 
without further purification.   
Device construction: 25 cylindrical rare earth magnets (N52 grade, 5mm OD x 1mm ID x 
5mm L, magnetized through the diameter) were strung along the length of a PTFE coated 
nitinol wire (Terumo Glidewire). IONP-HN3-DNA (1.0 g) was suspended in water and 
subsequently magnetically adhered to the surface of this device.  
Flow Model experiments: A closed-circuit flow model was used to measure doxorubicin 
clearance in a setting the simulates suprahepatic inferior vena cava conditions.1,2 In this 
model, the porcine blood is circulated through the polyvinyl chloride tubing at a rate of 
approximately 150 ml/min.  The tubing size matches the average human hepatic vein 
measuring 1.2 cm as described previously.3 Testing was performed with 200 ml porcine 
blood and samples were obtained from the tubing downstream from the device. 
 
In vivo porcine experiments: In vivo device testing was performed in farm swine (n=1, 45-
50 kg), which was under humane care.  Experimentation was under compliance with UCSF 
IACUC protocols. The animal was monitored with blood pressure, pulse oximetry, heart rate, 
and electrocardiogram while under general anesthesia with isoflurane. Using fluoroscopic 
guidance, an 18Fr sheath was placed into the left external iliac vein for introduction of the 
device. A pre-device sampling catheter was introduced through the right external iliac vein 
with the tip terminating in the left common iliac vein near the bifurcation. An additional 
catheter was introduced via the right internal jugular vein with the tip distal to the device in 
the IVC (post-device).  The mid-device catheter and peripheral catheters were introduced 
through the left internal jugular vein. Prior to the start of the experiments, patency of the 
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venous system was demonstrated using contrast injection (Omnipaque).  Doxorubicin was 
injected over ten minutes at a rate of 2.5 ml/min into the left common iliac vein proximal to 
the magnetic device. The pre-device doxorubicin concentration was measured by sampling 
with a 5 Fr catheter downstream of the doxorubicin infusion. Blood aliquots were taken 
proximal to, adjacent to the midpoint of, and distal to the device using separate catheters. To 
clear the sampling catheters, 2 mL of blood was drawn immediately prior to taking the aliquot 
(3 mL).  The blood samples were placed on ice until they were centrifuged to isolate the 
plasma fraction for analysis.  A control experiment was also performed using the same 
procedures but with no device inserted. 
Particle Synthesis: 
IONP-Pt: 3.31 g Magnetite (Fe3O4) was dried in vacuo at 120° Celsius. Upon cooling, the 
sealed material was introduced into an inert atmosphere nitrogen glovebox. To the magnetite 
was added 23 mL anhydrous toluene along with 4 mL N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane. The reaction was mechanically stirred on the bench at 110° 
Celsius for 2 hours and subsequently dried in vacuo at 110° Celsius for 20 hours. The reaction 
mixture along with 1.0 g K2PtCl4, was stirred at 70° Celsius for 21 minutes and then washed 
three times with water. Following this, the mixture was diluted to a total volume of 450 mL 
with 18.2 MΩ water was treated with 1.3 g KCl and an additional 10 mL water.  
IONP-Pt-DNA: IONP-Pt materials along with 5.1 g deoxyribonucleic acid from herring 
sperm were mechanically stirred in 450 mL 18.2 MΩ water at 37° Celsius for 20 hours. To 
ensure covalent attachment as opposed to being physically adsorbed, the particles were 
isolated from the reaction mixture, washed three times under vigorous mechanical stirring 
with 18.2 MΩ water (400 mL), frozen, and lyophilized to afford 3.08 g IONP-Pt-DNA.  
  
IONP-NH2: 4.2 g Of magnetite (Fe3O4) was dried in vacuo at 120° Celsius. The Fe3O4 was 
allowed to cool to room temperature under vacuum. To the Fe3O4 was added 25 mL toluene 
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(freshly dried over magnesium sulfate) and 3.2 mL 4-aminobutyltriethoxysilane. The 
reaction was sealed and stirred mechanically for 2 hours at 120° Celsius. The reaction was 
removed from heat and the particles were isolated from the toluene solution. The reaction 
mixture was washed once with toluene and subsequently dried in vacuo at 120° Celsius for 
1 hour and 45 minutes. 4.02 g of IONP-HN3 was isolated. 
IONP-HN3-DNA: 3.4750 g IONP-HN3 was added to a vial along with 1.02 g tris(2-
chloroethyl)amine hydrochloride and dimethylformamide (30 mL). The reaction was stirred 
mechanically for 1 hour at room temperature, at which point the particles were isolated from 
the dimethylformamide. The particles were then washed three times with 
dimethylformamide. The isolated particle as well as 3.35g deoxyribonucleic acid from 
herring sperm were transferred into a flask along with 400 mL 18.2 MΩ water. The reaction 
was mechanically stirred at 38° Celsius for 17 hours and 45 minutes. To ensure covalent 
attachment, the particles were then washed thoroughly under vigorous mechanical stirring 
three times with 18.2 MΩ water (400 mL) and magnetic separation. The particles were then 
frozen in liquid nitrogen and lyophilized to afford 3.79 g of IONP-HN3-DNA.  
Representative Binding Studies: 
DOX: To a scintillation vial was added 19 mL human serum. Drug was injected at a 
concentration of 1 mg/mL from a concentrated stock, to bring the total concentration to 
approximately .05 mg/mL. An initial time point is taken before drug capture. DNA particles 
(100±5 mg) is added to the serum mixture, which is constantly, mechanically stirred. 20 
seconds before a time point is taken, a strong, rare earth, magnet is used to isolate the particles 
at which point a 100 µL aliquot is taken and placed in a 96 plate microplate well. The 
solutions are then measured by way of fluorescence on a microplate reader. 
Cisplatin: Phosphate buffered saline solution (19 mL) was added to a scintillation vial.  
Cisplatin solution (1 mL, 1 mg/mL solution) was then injected, followed by 117±5 mg of 
IONP-HN3-DNA, and the mixture was mechanically stirred over the course of an hour. At 
predetermined time points the magnetic materials were temporarily isolated using an external 
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magnet so that 100 µL aliquots could be taken, which were diluted 200X in 2% nitric acid 
solution and subsequently analyzed by ICP-MS to determine the concentration of platinum 
remaining in solution.  
EPI: Human serum (19 mL) was added to a scintillation vial. EPI solution in water (1 mL, 
1 mg/mL solution) was then added. The particles (100±5 mg IONP-HN3-DNA) were then 
added and the solution was mechanically stirred over the course of 25 minutes. At 
predetermined time points, the magnetic materials were temporarily isolated using an 
external magnet and 100 µL aliquots were taken, which were subsequently diluted 100X in 
water and analyzed by fluorescence on a microplate reader in order to characterize the 
amount of EPI remaining in solution. 
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Supplementary Figure 1. In-vivo capture data for both control (no device) and IONP-
HN3-DNA coated device. 
 
Supplementary Figure 2. Full ATR-IR spectrum of magnetite, genomic DNA, and 
DNA-functionalized particles (IONP-HN3-DNA and IONP-Pt-DNA). 
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Supplementary Figure 3. ATR-IR spectrum (1800-400 cm-1) of magnetite, genomic 
DNA, and DNA-functionalized particles [IONP-HN3-DNA and IONP-Pt-DNA].4 
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Supplementary Figure 4. Reduction of cisplatin concentration over time due to capture 
by IONP-HN3-DNA particles, as characterized by ICP-MS. Cisplatin solution (20 mL, 
0.05 mg/mL) with 100 mg IONP-HN3-DNA. Average of three runs (error bars = 1 
standard deviation). 
 
 
Supplementary Figure 5. Reduction of EPI concentration over time due to capture by 
IONP-HN3-DNA as characterized by fluorescence measurements. EPI solution (20 mL, 
0.05 mg/mL) with 100 mg IONP-HN3-DNA. Average of three runs (error bars = 1 
standard deviation). 
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Supplementary Figure 6. DOX capture as a function of particle loading. Average of three 
runs (error bars = 1 standard deviation).  
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Supplementary Figure 7. DOX capture in 10 minutes from human serum (10 mL, 0.05 
mg/mL, 37 °C) as a function of amount of IONP-HN3-DNA added. Average of 3 runs, 
error bars = 1 standard deviation. 
 
 
 
 
Supplementary Figure 8. DOX capture in 7 minutes from human serum (10 mL, 0.05 
mg/mL, 37 °C) as a function of amount of IONP-HN3-DNA added. Average of 3 runs, 
error bars = 1 standard deviation. 
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Supplementary Figure 9. DOX capture in 4 minutes from human serum (10 mL, 0.05 
mg/mL, 37 °C) as a function of amount of IONP-HN3-DNA added. Average of 3 runs, 
error bars = 1 standard deviation. 
 
 
 
Supplementary Figure 10. DOX capture in 2 minutes from human serum (10 mL, 0.05 
mg/mL, 37 °C) as a function of amount of IONP-HN3-DNA added. Average of 3 runs, 
error bars = 1 standard deviation. 
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Supplementary Figure 11. DOX capture in 1 minute from human serum (10 mL, 0.05 
mg/mL, 37 °C) as a function of amount of IONP-HN3-DNA added. Average of 3 runs, 
error bars = 1 standard deviation. 
 
 
Supplementary Figure 12. SEM image of Fe3O4 particles. 
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Supplementary Figure 13. SEM image of Fe3O4 particle aggregates. 
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Supplementary Figure 14. EDS map and spectrum of Fe3O4 particle aggregates. 
  
100 
 
Supplementary Figure 15. EDS element maps of Fe3O4 particle aggregates. 
 
 
 
 
 
Supplementary Figure 16. SEM image of IONP-HN3-DNA. 
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Supplementary Figure 17. SEM image of IONP-HN3-DNA aggregates. 
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Supplementary Figure 18. EDS spectrum and map of IONP-HN3-DNA aggregates. 
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Supplementary Figure 19. EDS element maps of IONP-HN3-DNA aggregates. 
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Supplementary Figure 20. SEM image of IONP-Pt-DNA. 
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Supplementary Figure 21. SEM image of IONP-Pt-DNA aggregates. 
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Supplementary Figure 22. EDS map and spectrum of IONP-Pt-DNA aggregates. 
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Supplementary Figure 23. EDS element maps of IONP-Pt-DNA aggregates. 
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Supplementary Figure 24. SEM image of IONP-Pt aggregates. 
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Supplementary Figure 25. A. Doxorubicin clearance from porcine blood in closed loop 
flow model.  B. Closed loop flow model design with 25 magnet device within the lumen 
of the flow model. 
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Sample	ID	 %C	 %H	 %N	 Sample	mass	(mg)	
Fe3O4	
0.71	 0.44	 0.02	 19.78	
0.44	 0.37	 0.02	 9.267	
Average	 0.575	 0.405	 0.02	 14.5235	
Standard	
Deviation	 0.19	 0.05	 0	 -	
IONP-Pt-DNA	
5.27	 1	 2.15	 16.98	
5.28	 1.01	 2.14	 14.91	
Average	 5.275	 1.005	 2.145	 15.945	
Standard	
Deviation	 0.007	 0.007	 0.007	 -	
IONP-HN3-DNA	
6.6	 0.99	 2.64	 9.933	
6.51	 1.04	 2.6	 14.67	
Average	 6.555	 1.015	 2.62	 12.3015	
Standard	
Deviation	 0.06	 0.04	 0.03	 -	
Herring	DNA	 33.81	 4.61	 14.5	 3.666	
33.92	 4.66	 14.68	 7.386	
Average	 33.865	 4.635	 14.59	 5.526	
Standard	
Deviation	 0.08	 0.04	 0.13	 -	
 
Supplementary Table 1. Elemental analysis data for all materials. 
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